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INTRODUCTION
Gaining proper access to the circulation is a prerequisite for hemodialysis in order to transport 
blood from the patient to the artificial kidney and back to the patient again. In 1943, Dr. Willem 
J. Kolff first encountered the problem of gaining access to the bloodstream for hemodialysis (1). 
After 34 days of puncturing readily accessible blood vessels he failed to find further possibilities 
to enter the bloodstream. As a consequence his patient died. 
The chronic hemodialysis era began almost 20 years later, when Quinton and Scribner introduced 
the first external arterio-venous shunt constructed of Teflon, that allowed repeated access to the 
vascular system (2). Unfortunately, infection and thrombosis often limited the long-term use of 
this access type. In 1966 a major breakthrough in vascular access surgery was achieved by the 
introduction of the first endogenous fistula by Brescia and Cimino (3-5). They created a side-to-
side anastomosis  between  the  radial  artery  and  cephalic  vein,  which  ensured  function  as  a 
vascular access. Later, brachio-cephalic and transposed brachio-basilic fistulae were constructed 
by Dunlop (6) and Stonebridge (7) respectively. At present the arterio-venous fistula (AVF) is 
still considered to be the vascular access of choice. After adequate maturation, the AVF has the 
highest long-term patency rates because of  low risk of thrombosis and infection (8,9). 
Unfortunately,  creation of an AVF is not always possible as a consequence of prior vascular 
access  surgery,  or  insufficient  caliber  of  forearm  vessels.  Subsequently,  the  use  of  various 
prosthetic  grafts  has  emerged  as  an  alternative  to  native  fistula.  These  arterio-venous  grafts 
(AVG) are typically positioned in the forearm, in a looped or straight configuration. Nowadays, 
polytetrafluoroethylene (PTFE) is the most used  graft-material. Unfortunately, AVG appear to 
be associated with  a significantly higher risk of thrombosis and infection as compared with AVF 
(10-13). 
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Since the introduction of the AVF and the PTFE AVG, little improvement has been made in the 
vascular access field. Still, vascular access related complications are one of the most important 
reasons for patient hospitalisation, morbidity and even mortality (13,14). In the United States 
access complications are estimated to cost about to $1 billion per annum, and are responsible for 
17-30% of all hospital admissions in dialysis patients (15-17).  Interestingly,  the cost of vascular 
access related care was found to be more than fivefold higher for patients with AVG compared 
with patients with a functioning AVF (18). In an attempt to improve overall patency rates and 
reduce access related costs, the NFK-DOQI committee currently recommends that in any dialysis 
center the majority of new dialysis patients should have a primary AVF constructed (19).
Despite these recommendations large variations in vascular access practice patterns are found. 
Fistula use still is much lower in the United States than in Europe (9). AVF use was found to be 
actually 0% in some facilities in the United States (9). These differences are frequently attributed 
to unfavourable patient characteristics such as diabetes, peripheral vascular disease, and older age 
of patients  (9,20,21). However, the observed differences persist after adjustment for these patient 
characteristics. Facility’s preferences and approaches to vascular access practice still seem to be 
major determinants of vascular access use (22). 
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Endothelial function in chronic renal disease
Cardiovascular complications are a major cause of death and morbidity of ESRD patients (23). 
Early studies suggested that uremia is associated with accelerated atherosclerosis (24,25). Over 
the  last  decade  endothelial  dysfunction  has  been identified  as  an  important  mediator  in  this 
process. Nitric oxide (NO) is one of the main factors involved in the anti-atherosclerotic effects 
of  the  endothelium,  and  chronic  renal  failure  has  been  associated  with  impaired  NO 
bioavailability (26,27).
The ability to adjust to high blood flow and proper vasodilatation, needed after creation of AVF, 
could  be  strongly  influenced  by  endothelial  function  of  the  forearm  vessels.  Endothelium-
dependent vasodilatation of forearm capacitance vessels  is affected by many diseases, among 
which  several  are  known  to  cause  renal  failure,  like  diabetes  and  hypertension  (28).  Local 
infusion  of  vasodilators  causes  a  less  pronounced  increase  of  forearm flow in  hypertensive 
patients  as  compared  to  normotensive  controls  (29-35).  Also,  the  hyperaemic  response  after 
temporary arterial occlusion is reduced in hypertensive patients (29-34). Similar results are found 
in patients with diabetes and congestive heart failure (36,37). In addition, uraemia or so-called 
uraemic factors like homocysteine or endogenous inhibitors of NO-synthase (ADMA) could be 
directly toxic to the vascular endothelium (38,39). 
In addition to the impaired vasodilatation of capacitance vessels due to endothelial dysfunction, 
several authors demonstrated reduced venous forearm distensibility in patients with hypertension, 
diabetes,  chronic heart  failure and end stage renal disease (40-43). Vein wall distensibility is 
controlled by collagen,  elastin and smooth muscle.  Wali et  al.  demonstrated accumulation of 
collagen fibres in place of smooth muscle cells in pre-access cephalic veins, which would cause a 
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decrease  in  the  elasticity  of  the  vein  wall  (44).  These  functional  properties  of  the  forearm 
vasculature could interfere with proper maturation of the AVF.
Increasing the placement of AVF and an aggressive policy for vascular access monitoring could 
improve quality of life and overall outcomes for hemodialysis patients significantly. 
Choice of access: preoperative testing
With  the  recognition  of  the  superiority  of  the  AVF  and  the  increasing  comorbidity  of  the 
hemodialysis population, efforts are made to evaluate the vasculature of the arm of the patient 
prior to access surgery. This would help the surgeon to choose the access site and type with the 
highest  likelihood  of  success  in  the  individual  patient.  The  NKF-DOQI  guidelines  provide 
recommendations  concerning  preoperative  evaluation  in  addition  to  obtaining  careful  patient 
history and physical examination of the patient’s venous venous, arterial, and cardiopulmonary 
systems (10). In patients who meet specified criteria such as edema of the extremity, collateral 
vein  development,  or  previous  subclavian  catheter  placement,  venography  is  indicated.  In 
compare to Doppler studies, venography has the advantage of accurate evaluation of central vein 
structures.  However,  patients  with  reduced  kidney  function  in  whom  contrast  agents  are 
undesirable, Doppler ultrasound or magnetic resonance imaging may be preferred. 
Preoperative Doppler ultrasound
Doppler ultrasound has been the most extensively studied and widely used test to guide access 
creation (45-51). Several authors demonstrated that vessel size and blood flow are of predictive 
value for AVF outcome. AVF creation with a cephalic vein and/or radial artery smaller than 1,5-
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2,0 mm is likely to fail and may indicate brachio-cephalic or transposed brachio-basilic AVF or 
insertion of a graft (45,52,53). A pre-operative brachial artery flow of at least 40 mL/min and a 
flow of 400 mL/min or more in the subclavian vein are associated with better primary patency 
rates and fistula function (47). Also, the use of a standardized program of preoperative arterial en 
venous mapping with ultrasonography could increase the use of AVF and reduce early failure 
rates (48,50,54).
Forearm strain-gauge  plethysmography
Venous occlusion strain-gauge plethysmography is a frequently used technique for measurement 
of forearm blood flow and venous compliance (55). Throughout the years the method has been 
standardized and computerized, resulting in a reasonably simple and reliable technique (56-58).
It works on the principle that during short-term occlusion of venous return, the rate of distension 
of the forearm is proportional to the rate of arterial inflow into the forearm. Provided that the 
arterial blood pressure remains constant, changes in flow reflect changes in smooth muscle tone 
in small  arteries  and arterioles.  A venous occlusion upper  arm cuff  is  rapidly inflated to 60 
mmHg during 4 heartbeats and deflated during 3 heartbeats. Distension of the arm is detected by 
a length transducer  -  specifically,  a fine rubber tube containing mercury -  placed around the 
maximal  circumference  of  the  forearm.  The  influence  of  the  circulation  of  the  hand  on  the 
measurements of forearm blood flow (FBF) is only small, which makes the use of a wrist cuff 
unnecessary (55). Subjects lay in supine position with the arm supported above heart level. 
FBF can be measured at rest and after arterial infusion of drugs. FBF is expressed as mL blood 
flow/min/100ml forearm. Incremental infusions of acetylcholine, metacholine or serotonine are 
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frequently used drugs to examine endothelium-dependent vasodilatation. Sodium nitroprusside 
(SNP) is the most frequent used drug to examine endothelium-independent vasodilatation. 
Venous compliance is the change in blood volume for a given change in pressure produced by a 
cuff around the arms or legs. The cuff pressure restricts blood flow from the tissues and causes 
the blood to pool. The upper arm cuff is inflated to a cuff pressure of 20 mmHg and is kept 
inflated during 3 minutes for stabilization of arm volume and venous pressure values. The cuff is 
deflated for 2 minutes to minimize accumulation of interstitial fluid due to capillary filtration. 
After  repeating the same procedure during cuff pressures of 30, 40,  50 and 60,  the obtained 
volume/pressure  ratios  are  used in a  linear  regression analysis  to  obtain the volume-pressure 
relationship as an estimate of venous compliance.
So far, the value of forearm venous compliance and blood flow prior to AVF creation has never 
been evaluated. This thesis presents two studies that focus on this subject.
Preoperative magnetic resonance venography
Preoperative use of magnetic resonance (MR) venography and its advantage over conventional 
contrast-enhanced  venography  was  documented  by  Menegazzo  et  al  (59).  Although  it  is 
considered non-invasive and safe, the quality of the basilic and central veins cannot be assessed, 
which is a major drawback of the MR venography (60). Furthermore, the cost-effectiveness of 
MR venography is questionable.
Prevention of vascular access thrombosis
In AVG, most thrombotic events result from one or more progressive stenoses in the venous 
outflow tract, typically at the venous anastomosis (61-64). These stenoses are caused by intimal 
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and fibromuscular hyperplasia (65,66). Any obstruction to the outflow from the graft will result 
in an increase in venous pressure in the dialysis circuit with an accompanying decrease in blood 
flow (67). Stenoses in AVF tend to occur more centrally at vein bifurcations and venous valves, 
rather  than close  to the  venous outlet.  Stenoses  in  AVF frequently  result  in  development  of 
collateral veins draining the AVF. As a result, a venous stenosis will cause a reduction in blood 
flow but often without the increase in venous pressure. Arterial inflow stenoses account for less 
than 5% of lesions in accesses (67).
Prospective  surveillance  of  vascular  accesses  for  hemodynamically  significant  stenoses,  and 
subsequent  referring  for  percutaneous  transluminal  angioplasty  (PTA)  or  surgical  revision, 
improves patency rates and decreases the incidence of thrombosis (Kanterman 1995, Besarab 
1995, Beathard 1995, Windus 62,64,68,69). At present, access flow (Qa) and venous pressure 
measurements are preferred techniques that can be used in surveillance of both AVG and AVF 
(10).
Access flow
Several  methods  are  available  for  measuring  access  flow  (Qa).  The  most  widely  used  and 
validated method is the ultrasound dilution technique, first introduced by Krivitski (70-73). It is 
based  on  the  Fick-principle:  dilution  of  blood  in  the  extracorporeal  circuit  is  measured  by 
ultrasound. (70). 
Although it  is known that  low-flow circumstances provoke thrombosis,  the optimal threshold 
level for intervention has not been definitively determined. A limited number of studies using 
serial access flow measurements, suggest that grafts showing a flow between 500 and 800 ml/min 
are at risk for thrombosis (74-76). This has led to the general recommendation that intervention 
should be considered in patients with flows less than 600 ml/min (10). A trend of decreasing 
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access flow could be more predictive of venous stenosis than a single access flow measurement, 
however studies on this subject show conflicting results (77,78). Paulson et al. demonstrated that 
a decrease in flow had a sensitivity of 80%, but had a false-positive rate of 30% (78). This may 
lead to unnecessary interventions. Still, the NKF-K/DOQI committee recommends referral for 
angiography in patients with access flows less than 1000 ml/min, who show a decrease of more 
than  25%  over  4  months  time  (10).  Much  less  evidence  is  available  on  the  value  of  flow 
measurements  in AVF. Flow measurement  in  AVF is unreliable  when needles are  placed in 
collateral veins, and the optimal threshold for predicting failure of AVF has not been determined. 
More important, the incidence or thrombosis in fully matured AVF is very low, which makes it 
very difficult to evaluate the effect of flow-based monitoring strategies on reducing thrombosis of 
AVF.  However,  a  flow-based  surveillance  program with  prophylactic  PTA  of  stenoses  was 
shown  to  effectively  reduce  thrombosis  rates  and  access-related  morbidity  in  a  prospective 
controlled trial (79).
Venous pressure
Dynamic and static venous pressure measurements are used for access surveillance. Schwab et al. 
introduced  the  dynamic  venous  pressure  measurement:  venous  drip  chamber  pressure  was 
measured at a pump flow rate of 200-225 mL/min (80). Persistently elevated venous pressure 
predicted the presence of significant venous stenosis (80). A reduction of thrombotic rate from 
0.49 to 0.20 was demonstrated with graft surveillance using dynamic venous pressure monitoring 
and elective repair when compared to historical controls (80,81). Schwab et el. also included 
AVF.
However, dynamic venous pressure is importantly influenced by pump flow, needle gauge, blood 
tubing  and  blood  pressure  (82).  This  problem can  be  overcome by measuring  static  venous 
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pressure.  Besarab et  al.  developed a  method to measure venous pressure at  zero pump flow, 
corrected for mean arterial blood pressure (VP0/MAP). Referral for angiography and subsequent 
intevention of significant stenoses in patients with VP0/MAP  ≥ 0.50, resulted in a decrease in 
thrombosis rate from 57 to 17 per 100 patient years (68). Again, AVF and AVG were included. 
An increased thrombotic tendency is an important cause of complications in patients on chronic 
hemodialysis. Still, the relationship between hypercoagulability and vascular access thrombosis is 
largely  unknown.  At  present,  no  evidence-based  consensus  has  been  established  regarding 
pharmacological  prevention  of  access  prevention.  The  coagulability  abnormalities  leading  to 
thrombotic tendency in chronic hemodialysis patients will be discussed in this thesis.
Treatment of vascular access stenosis and thrombosis
Access  stenosis  and  thrombosis  are  treated  either  radiologically  or  surgically.  Prior  to  the 
introduction of access surveillance programs the most common clinical presentation of access 
failure  was  thrombosis.  Traditionally,  surgical  thrombectomy  with  or  without  revision  was 
utilized for dialysis access salvation. Surgical therapy has the advantage of elimination of the 
lesion.  However,  this  has  the  great  disadvantage  of  loss  of  potential  access  puncture  sites. 
Considering the recurrent nature of venous stenosis, this may cause vascular access problems 
over time. Although literature reports slightly better patency rates after surgical correction of 
stenosis (83), general opinions are in favour of percutaneous treatment, because of the previously 
mentioned disadvantage together with the need for hospitalization.
Nowadays,  patients  often  present  with  access  stenosis,  which  is  primarily  treated  with 
percutaneous transluminal angioplasty (PTA). Angioplasty is a safe outpatient procedure, which 
can be successfully repeated if necessary (84). Compared with surgery, PTA has the advantage of 
14
preserving access sites. Also, even centrally located stenoses are accessible. Initial success rates 
of PTA range from 80 to 94% (62,85,86). The highest rate of technical failure is associated with 
central  lesions  (84).  Primary  patency  rates  at  6  months  after  PTA  range  from  43  to  77% 
(61,62,84,87), again with poorest long-term success in central lesions (nearly 25% at 6 months, 
84). Results after vascular access thrombosis are generally worse, with a reported patency rate of 
only 19% in one study (88). Additive placement of self-expanding stents should be considered 
only in a  selected group of  patients,  with central  -elastic-  lesions not responsive to PTA,  or 
recurrence within 3 months after successful PTA, and patients with vein rupture after PTA (89). 
Lesions that cannot be dilated with angioplasty should not be treated with stent placement.
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AIM AND OUTLINE OF THE THESIS
This thesis comprises 5 studies concerning two major hemodialysis vascular access issues: 
Preoperative management in patients awaiting vascular surgery 
With  the  recognition  of  the  superiority  of  the  AVF  and  the  increasing  comorbidity  of  the 
hemodialysis population, efforts are made to evaluate the vasculature of the arm of the patient 
prior to access surgery. Decision-making on which type of vascular access –AVF or AVG- is best 
suitable  for  the  individual  patient,  is  notoriously  difficult  and  based  on  surgeons’  personal 
opinion of  the  quality  of  the  forearm vasculature  or  on  static  anatomical  data  derived  from 
Duplex ultrasonography. So far, the impact of functional parameters of forearm vasculature prior 
to surgery on the success of newly created AVF, has never been studied. In chapter 3 and 4 we 
examine the predictive value of both venous and arterial  wall  properties  in the outcome and 
maturation of AVF, using the technique of venous occlusion plethysmography.
Chapter 3. Forearm venous distensibility
In this chapter we examine the importance of pre-operative forearm venous distensibility with 
respect  to  AVF  maturation.  I.e.  what  is  the  impact  of  functional  properties,  in  addition  to 
anatomy of the forearm venous vasculature on the outcome of newly created AVF? After AVF 
creation, flow increases as a result of both vasodilatation and vascular remodeling. In several 
animal models of flow-induced vasodilatation, endothelial cells play an important role in vascular 
remodeling (1-5). Defective endothelial vasodilator function has been demonstrated in patients 
with different stages of renal failure (6). Forearm venous distensibility, i.e. the ability to adjust to 
blood pressure is also impaired in these patients. It is suggested that venous distensibility is also 
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influenced by endothelial  funtion (7). It  is  not known whether  impaired venous distensibility 
results in AVF failure. Hence, we measured this venous functional parameter in patients with 
end-stage renal failure awaiting vascular access surgery and investigated its predictive role in 
AVF failure. Furthermore, the results of plethysmography were compared to the pre-operative 
Duplex ultrasonography data. 
Chapter 4. Forearm blood flow capacity
After creation of an AVF for hemodialysis, blood flow through the radial artery will increase as a 
result of vasodilatation and vascular remodeling (8). This adaptive response appears to be crucial 
in reducing wall shear stress to baseline values. Major calcification and stiffening of the radial 
artery wall will inhibit proper vasodilatation, which will lead to inadequate arterial inflow of the 
AVF. Vasodilatation after AVF-creation is primarily caused by acute release of nitric oxide by 
endothelial  cells,  so-called  endothelium-dependent  vasodilatation. We  hypothesized  that  the 
forearm blood flow capacity, i.e. the increase of forearm blood flow as a result of vasodilatation, 
is an important determinant of failure of newly created AVF in hemodialysis patients. Therefore, 
in this chapter,  we determine whether forearm blood flow capacity in patients with end-stage 
renal failure awaiting vascular access surgery, is predictive of early failure. To discriminate the 
influence of the endothelium in early fistula failure, we measure both, endothelium dependent 
and  endothelium  independent  forearm  vasodilatation,  using  forearm  venous  occlusion 
plethysmography. 
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Prevention of vascular access thrombosis
Once the vascular access, whether AVF or AVG has been placed, another important problem 
arises: thrombosis. In chapter 5 strategies to identify AVG at risk of thrombosis, i.e. vascular 
access  stenosis,  are  studied.  It  has been demonstrated that  timely treatment  of  these stenotic 
lesions results in less thrombotic events. Chapter 6 will focus on short- and long-term functional 
effects  of  percutaneous  treatment  of  stenoses  in  AVG  and  AVF.  Chapter  7  reviews  the 
hypercoagulable state in hemodialysis patients.
Chapter 5. Graft surveillance
Thrombosis occurs at a rate of 0.5 to 2.5 events per patient-year (9-13). In most cases thrombosis 
is associated with the presence of stenoses at the venous anastomosis or in the outflow tract (14-
18). Stenosis increases resistance over the flow tract. Because the graft has no autoregulating 
capacities,  blood flow (Qa) drops and venous pressures (VP) rise. These variables have been 
shown to predict  thrombosis. More importantly, several studies demonstrated that referral for 
corrective intervention based on these parameters can prevent thrombosis (19-23). Whereas, VP 
only  reflects  outflow  resistance,  Qa  reflects  total  graft  resistance.  This  raises  the  following 
questions:  Are Qa measurements  superior  to  VP measurements  with regard to prevention of 
access thrombosis? Are Qa measurements of benefit when added to a surveillance protocol using 
simple VP measurements? In this prospective, randomized study we examine whether referral of 
patients for corrective interventions based on Qa measurements alone or on the combination of 
VP and Qa indeed reduces thrombosis rate more than referral based on VP alone.
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Chapter 6. Functional effect of percutaneous transluminal angioplasty
Percutaneous transluminal angioplasty (PTA) is an accepted treatment of stenotic lesions (3)24). 
Routine surveillance programs for the early detection of stenoses followed by angioplasty have 
been  shown  to  substantially  reduce  the  number  of  thromboses  per  patient  year  (17,19,21). 
However,  repetitive  PTA  treatment  is  often  necessary,  since  re-stenosis  frequently  occurs. 
Although the short term success rates of PTA range from 85% to 98%(29), patency at 6 months 
follow-up varies from 38% to 63% (15,20,25,26). Several studies have shown that angiographic 
degree of the stenotic lesion before and after PTA is poorly related with its subsequent patency 
(9,11-14),15,20,27-29). In particular,  access flow (Qa) measurements  offer the opportunity to 
quantify and follow up the functional effect of PTA. The purpose of this study is to assess access 
function of patients undergoing PTA. We quantify the short-term functional and angiographic 
effect of PTA. In addition, we determine the longevity of the functional effect during follow-up. 
Finally,  we  addresse  the  question,  whether  functional  variables  are  predictive  of  long-term 
outcome.
Chapter 7. Coagulation and hemodialysis access thrombosis
In  most  cases  thrombosis  is  associated  with  low  access  blood  flow  (23,30,31).  The  most 
important  reason for  a  decreasing  access  blood flow is  intimal  hyperplasia  formation  at  the 
venous anastomosis or in the outflow tract of the graft (14-17). However, not all decreases in 
access  blood  flow  are  related  to  intimal  hyperplasia  or  stenosis  formation.  An  increased 
thrombotic tendency is an important cause of complications in patients on chronic hemodialysis 
leading to complications like ischaemic heart disease or stroke. There has been a growing interest 
in  the  role  of  increased  hypercoagulability  in  access  thrombosis.  This  review  will  discuss 
coagulability  abnormalities  in  relation  to  hemodialysis  access  thrombosis.  We will  focus  on 
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coagulation abnormalities leading to the thrombotic tendency in chronic haemodialysis patients. 
And finally, preventative measures for these coagulation defects will be discussed.
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Abstract
Background. The success of a newly created arterio-venous fistula (AVF) depends on sufficient 
maturation of the forearm vein used. This maturation fails in up to 30%. We hypothesize that 
impairment  of  forearm  venous  distensibility  (VD),  i.e.  the  ability  of  veins  to  adjust  to  an 
increased pressure, is related to AVF failure. 
Methods. Forearm VD was measured using strain-gauge plethysmography, in 27 patients with 
end stage renal failure awaiting vascular access surgery, either AVF or graft (AVG). Ultrasound 
duplex scanning of the upper  extremity circulation was performed 4 weeks prior  to  surgery. 
Failure to mature was defined as the inability to use the AVF for hemodialysis within 8 weeks 
after surgery.
Results. VD  in  patients  receiving  AVG  (n=10)  was  0.44±0.05  mL/mmHg, VD  in  patients 
receiving AVF (n=17) was  0.56±0.04 mL/mmHg (p=0.2). VD in patients with an unsuccessful 
AVF (n=9) was  0.46±0.03 mL/mmHg and 0.66±0.05 mL/mmHg  in patients with a successful 
AVF (n=8)(p=0.003). All 7 patients with VD 0.50 mL/mmHg or less had a non-functional AVF 
(100%). Whereas only 2 out of 10 patients with VD higher than 0.50 mL/mmHg had a non-
functional  AVF  (20%)(p=0.002).  No  differences  were  found  in  arterial  and  venous  luminal 
diameters between  functional and non-functional AVF.
Conclusions. These preliminary results suggest that forearm VD is a predictor of AVF success, 
whereas luminal diameters are not. Measurement of VD may be helpful in choosing the most 
suitable access type for each individual patient, possibly improving access patency.
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Introduction
Long-term functioning of a  vascular access is of crucial importance in hemodialysis patients. 
Because  of  better  primary  and  secondary  patency  rates  and  less  infectious  and  thrombotic 
complications  in  comparison  to  prosthetic  grafts  using  polytetrafluoroethylene  (AVG),  the 
primary  arterio-venous  (AVF),  i.e.  autologous  radiocephalic  fistula,  is  considered  to  be  the 
vascular access of first choice (1,2). Therefore, recent K-DOQI guidelines recommend that at 
least 50% of new hemodialysis patients  should have a primary AVF  leading to better patency 
rates and less access related costs (3).
Adequate maturation of AVF, i.e.  sufficient dilatation and arterialization, is a prerequisite for 
repeated cannulation for haemodialysis treatment. Early successful maturation of an AVF appears 
to be a strong predictor of long-term function (4,5). However, depending on patient selection, 
maturation fails  in  up to 30% of all  newly created fistulas,  resulting in delayed initiation of 
dialysis treatment or placement of temporary central venous dialysis catheters, with their related 
morbidity (6-10). These early failures are frequently regarded as a technical failure, but factors 
like age, gender, blood pressure and associated illnesses are likely involved in AVF maturation as 
well (7,11). 
Decision-making  on  which  type  of  vascular  access  –AVF or  AVG-  is  best  suitable  for  the 
individual patient, is notoriously difficult and based on surgeons’ personal opinion of the quality 
of the forearm vasculature or on static anatomical data derived from Duplex ultrasonography. 
Recently, the use of  preoperative venous mapping, was shown to not only increase the number of 
created AVF’s, but also to nearly double patency rates and reduce the early failure rate from 36 to 
8.3% (8). Several studies demonstrated a relationship between preoperative vessel diameter and 
AVF success (9,12-14). However, these studies have shown various results and many used AVF 
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patency,  rather  than  the  ability  to  provide  adequate  blood  flow on  hemodialysis  as  primary 
outcome.
After AVF creation, flow increases as a result of both vasodilatation and vascular remodeling. In 
several animal models of flow-induced vasodilatation, endothelial cells play an important role in 
vascular remodeling, but the mechanism is still unclear (15-19
).  In  patients  with  diabetes,  hypertension  and  heart  failure  endothelial  vasodilator  function 
appears to be impaired (20).  Also,  in patients  with different  stages of renal  failure  defective 
endothelial  vasodilator  function  has  been  demonstrated  (21).  Interestingly,  venous  forearm 
distensibility (VD), i.e. the ability of veins to adjust to increased pressure is also impaired in these 
patients (22).
We hypothesized that the dynamic properties of the forearm venous vasculature are an important 
determinant of the maturation of newly created AVF’s in hemodialysis patients. Therefore we 
determined whether forearm VD in patients with end-stage renal failure awaiting vascular access 
surgery,  was  predictive  of  early  successful  AVF  maturation.  Furthermore,  the  results  of 
plethysmography were compared to the pre-operative Duplex ultrasonography data. 
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Subjects and methods
Subjects
Patients  with  advanced  renal  failure,  requiring  hemodialysis  and  awaiting  vascular  access 
surgery, were recruited consecutively. The institute’s Medical Ethics Committee approved the 
trial protocol. Written informed consent was obtained from all participating patients. The patients 
were asked to refrain from smoking and caffeine or alcohol containing beverages for at least 12 
hours prior to the study. Vasoactive medication was discontinued 7 days before the study. Within 
one  month after  Duplex  ultrasonography and forearm strain  gauge plethysmography patients 
underwent vascular access surgery. The vascular surgeon decided the access type -either arterio-
venous  fistula  (AVF)  or  graft  (AVG)-  based  on  physical  examination  and  preoperatively 
determined  duplex parameters.  Patients  with  no visible  and/or  a  tortuous  short  cephalic  vein 
and/or radial artery diameter less than 1.5 mm received an AVG. 
Patients who received an AVF were further evaluated after surgery.  The following data were 
collected: Duplex ultrasound access flow one day after surgery, duration of hospitalization and 
complications. A non-functional AVF was defined as the inability to use the AVF for two-needle 
hemodialysis within 8 weeks of surgery, judged by a panel of experienced dialysis nurses, who 
were unaware of the results of all additional forearm studies. Successful dialysis was defined as 
the ability to provide at least 250 mL/min dialyzer pump flow.
Duplex ultrasonography
Pre-operative  duplex  scanning  of  the  upper  extremity  was  performed  with  the  HDI  3000 
Ultrasound System (ATL Ultrasound Bothell, USA). A 2-D linear electronic probe, pulse wave 
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Doppler and color wave Doppler at 5.0 MHz were used. The internal diameters of the cephalic 
vein and the radial  artery at  the wrist,  and the brachial  artery were measured using M-mode 
technique. A tourniquet to increase vascular size was not used. The flow (mL/min) of the brachial 
and  radial  arteries  was  obtained  using  the  transducer  frequency,  the  Doppler  angle  and  the 
measured Doppler shift. Blood flow  was calculated as the product of  time-averaged velocity 
(TAV: cm  × sec-1) and  cross sectional area (A; cm2) of the arteries. The patency of both the 
proximal cephalic and subclavian vein was examined and their internal diameter was measured. 
Measurements were performed within one month prior to surgery. One day after AVF creation 
duplex AVF flow (mL/min) was measured at the venous side of the anastomosis.
Forearm strain-gauge plethysmography
The experiments were performed in the afternoon in quiet air-conditioned room with an ambient 
temperature of 22ºC. Subjects were studied in supine position with arms supported 10 cm above 
the level of the right atrium. The arm chosen for vascular access surgery, which was the non-
dominant  arm in the  majority  of subjects,  was used for measurements.  A mercury-in-silastic 
strain  gauge  was  positioned  around  the  widest  part  of  the  forearm.  The  strain  gauge  was 
connected to a plethysmograph (model periflow SU 4, Janssen Scientific Instruments, Beerse, 
Belgium) with electronic calibration for percentual volume changes and a built-in flow integrator 
module. To enable off-line data analysis, the plethysmograph was connected to an A/D converter 
(Dataq Instruments, model DI 420, Akron, OH, USA) for electronic data storage. A cuff was 
placed around the upper arm. Inflation was achieved using an ECG-triggered rapid cuff inflator 
(Janssen Scientific Instruments). Blood pressure and heart rate were measured continuously using 
the Finapress blood pressure monitor (Ohmeda, Inglewood, CO, USA). 
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Venous distensibility protocol
VD was determined as described by Kooman (22). After a 30-minute rest period, the upper arm 
cuff was inflated to a cuff pressure of 20 mmHg and was kept inflated during 3 minutes for 
stabilization of arm volume and venous pressure values. The cuff was deflated for 2 minutes to 
minimize accumulation of interstitial fluid due to capillary filtration. The changes in volume (dV, 
mL/100ml-1 forearm) during each cuff  pressure  step  (dP,  in  mmHg) were obtained from the 
values measured just before and after deflation of the cuff. The dV was corrected for forearm 
volume, which was measured using a column filled with water to a fixed level (dV, mL). Cuff 
pressure  was used (23,24)  as  an estimate  of  venous pressure  (VPc).  Subsequently,  the  same 
procedures were followed to obtain volume/pressure ratios during cuff pressures of 30, 40, 50 
and 60 mmHg. The ratios of dV and VPc were used in a linear regression analysis to obtain the 
volume-pressure relationship as an estimate for VD (mL/mmHg).
Statistics
For  comparison  of  individual  data  between  groups  2-sided  t-test  analysis  was  used.  Linear 
regression analysis was used to calculate correlations between datasets. A  p-value of less than 
0.05 was considered significant.
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Results
Twenty-seven patients with end stage renal disease awaiting vascular access surgery either for 
AVF or AVG participated in the study. In seventeen patients an AVF was created, the remaining 
10 patients received an AVG. Patient characteristics are summarized  in table 1. 
Table 1. Patient characteristics
Arterio-venous fistula
Functional Non-functional
Arterio-venous graft
n=8 n=9 n=10
age (years)* 56 (32-83) 59 (35-78) 62 (30-81)
gender (m/f) 8/0 6/3 2/8
serum creatinine (mg/dl)* 7.7 (5.2-9.9) 8.4 (5.3-11.3) 7.5 (5.8-12.2)
diabetes (n) 0 1 2
hypertension (n) 7 8 7
smoking (n) 2 3 0
peripheral vascular 
disease (n)
0 3 2
NOTE. To convert serum creatinine in mg/dL to µmol/L, multiply by 88.4.
* data are presented as mean and range 
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Venous distensibility
VD of patients receiving AVG (n=10) was 0.44±0.05 mL/mmHg and 0.56±0.04 mL/mmHg in 
patients receiving AVF (n=17)(p=0.2). VD in patients with an unsuccessful AVF eight weeks 
after surgery (AVF-, n=9) was 0.46±0.03 mL/mmHg, while in patients with a successful AVF 
(AVF+,  n=8)  VD  was  0.66±0.05  mL/mmHg  (p=0.003,  Figure  1).  The  mean  duration  of 
hospitalization  was  5.3  days  (range  1-21  days)  in  AVF-  and  3.6  days  (1-8  days)  in  AVF+ 
(p=0.53). 
Figure 1 shows that all 7 patients with VD of 0.50 mL/mmHg or lower had a non-functional AVF 
(100%).  Only 2 out of 10 patients with VD higher than 0.50 mL/mmHg had a non-functional 
AVF  (20%).  This  difference  was  statistically  significant  by  Fisher’s  exact  test  (p=0.002). 
Application of this criterion yielded a sensitivity of 100% (8/8), a specificity of 78% (7/9), a 
positive  predictive  value  of  80% (8/10)  and a  negative  predictive  value  of  100% (7/7).  The 
outcome of 15 patients was correctly predicted by VD (88%).
Two patients with non-functional AVF had VD above 0.50 mL/mmHg. Angiography showed a 
severe venous stenosis a few centimeters from the anastomosis in both AVF. A pseudoaneurysm 
was seen at the stenotic region in one AVF. Both AVF’s were surgically revised 3 months after 
the first operation. One AVF could be used for hemodialysis after revision, the other occluded. 
Of the other 7 non-functional AVF 3 never matured: these patients went for secondary access 
surgery. Four AVF’s could be cannulated for hemodialysis only after 100 days (range 84-132 
days).  Angiography showed an arterial stenosis in one patient and a venous stenosis and with 
extended collateral circulation in another. After 3 percutaneous transluminal angioplasty (PTA) 
procedures these AVF could be used for dialysis. The remaining 2 AVF showed no significant 
stenoses at angiography and finally matured.
46
No differences were found in the brachial and radial artery and cephalic vein luminal diameters 
between  AVF+ and AVF- . No significant correlation was found between VD and cephalic vein 
diameter. Results of preoperative duplex ultrasonography are depicted in more detail in table 2. 
Table 2. Duplex ultrasonography data of patients with AVF
Functional AVF Non-functional AVF
n=8 n=9
Luminal diameter (mm)* 
• Radial artery 2.1±0.1 2.0±0.2 Ns
• Brachial artery 4.3±0.4 4.1±0.3 Ns
• Cephalic vein 1.9±0.4 1.9±0.2 Ns
• Subclavian vein 8.0±1.3 8.5±0.7 Ns
Brachial artery flow (mL/min)* 44.1±13.8 34.3±8.0 Ns
* data are presented as mean±sd 
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Discussion
This  prospective  study evaluates  venous forearm function rather  than anatomy prior  to AVF 
creation  for  the  first  time.  The  results  of  this  study  support  our  hypothesis  that  apart  from 
structural  changes,  the  functional  properties  of  forearm veins  are  important  in  the  adaptive 
response to increased blood flow after AVF creation. Furthermore, functional data of forearm 
venous vasculature do not correspond with anatomical data. Our data suggest that VD predicts 
successful AVF maturation, whereas venous and arterial diameters do not. 
Previous  studies  found  that  in  patients  with  end-stage  renal  failure  forearm  veins  are  less 
distensible in comparison to healthy controls (22,25). Several authors reported increased venous 
intimal and media thickness in renal failure (26,27). Wali et al. showed accumulation of collagen 
fibers  in  the  vein  wall  (27).  Also,  venous  wall  edema  may  account  for  decreased  venous 
distensibility (28). The importance of endothelial function in arterial vasodilatation after AVF 
creation is demonstrated by several authors (15-19). In addition, Tronc et al. (15) demonstrated 
less venous dilatation in response to increased blood flow in L-NAME treated rabbits, suggesting 
a critical role of the endothelial cells in venous remodeling as well. However, the influence of the 
endothelium on VD remains to be elucidated. 
Studies on the use of ultrasound prior to AVF creation have shown varying results and many 
have used AVF patency as primary outcome rather than the ability to provide adequate blood 
flow for hemodialysis (13,14). Our study could not demonstrate differences in success rates at 
any cut-off point for radial artery or cephalic vein diameter. This is in contrast with the a post hoc 
analysis of Wong et al., who showed that luminal radial artery or cephalic vein diameter of less 
than 1.6 mm was associated with AVF failure (14). Actually, only 6 out of 60 patients had vessel 
diameters this small. Malovr et al described a significant difference in success rate of patients 
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with a radial artery diameter of 1.5 mm or less (45%) and patients with a radial artery diameter 
above 1.5 mm (92%)(13). However, definition of AVF failure was not provided in this study. 
This difference in study results can, at least in part, be explained by our study design, which 
selected patients with a radial artery diameter under 1.5 mm for AVG. The question whether 
these patients can undergo AVF creation successfully, cannot be answered definitively. 
Numerous studies have evaluated the utility of Doppler ultrasound access flow in the immediate 
postoperative  period  subsequent  to  AVF  creation  (6,14,29-31).  Although  several  authors 
(6,29,30)  demonstrated  higher  intraoperative  access  flow in  successful  AVF,  others  failed to 
show any correlation between intraoperative access flow and outcome (14,31). This difference is 
frequently attributed to vessel spasm during operation, resulting in poor fistula flow. This would 
explain the better  correlation between 1-day postoperative  access  flow and AVF outcome as 
demonstrated by Wong et al. (14). In our study, day one postoperative duplex flow was measured 
in 12 patients, and was also found to be higher in functional AVF (n=6) when compared to non-
functional  AVF (n=6),  however  large  variations  were  found within  both groups,  limiting  its 
predictive value in clinical practice (data not shown). 
The majority of female patients received AVG in our study. Several studies have reported that 
female patients are much less likely to dialyze with a fistula (2,32,33). VD was significantly 
higher in males (p=0.0002). Also, female patients were found to have smaller radial arteries and 
cephalic  veins  (data  not  shown).  Thus,  both  functional  and  anatomical  differences  must  be 
responsible for this observation. 
Our  study  has  certain  limitations.  Because  of  the  limited  number  of  patients,  the  effect  of 
confounding factors on our results could not be evaluated. Indeed, factors like peripheral vascular 
disease, female gender and diabetes may have influenced VD in a negative way in the group of 
patients with non-functional AVF’s. However, currently these factors are never used to select 
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access  type  in  daily  clinical  practice.  VD,  on  the  other  hand,  possibly  reflects  endothelial 
dysfunction in these patients, and may be used as a practical tool to estimate the risk of AVF 
failure in the individual patient. 
The time required for fistula maturation varies among patients. We have chosen an arbitrary time 
period of 8 weeks in our study, which is in agreement with DOQI guidelines (3). The Work 
Group  does  not  advise  use  of  the  fistula  within  the  first  month  after  construction  because 
premature cannulation of a fistula may result in a higher incidence of infiltration with associated 
compression of the vessel by hematoma and permanent loss of the fistula. Allowing the fistula to 
mature for 3 months before use may be ideal. However, the Work Group did not reach consensus 
on this topic. In fact, allowing 3-month maturation would not have changed our results, since 
final cannulation in the 5 patients in the non-functional AVF group, was only possible after 100 
days, usually after PTA or surgical revision. Furthermore, patients with functional AVF’s were 
cannulated after 41 days.
Considering our data provided proof of the principle that functional vessel wall characteristics 
predict fistula maturation, the preoperative evaluation of the forearm vasculature should not only 
focus on resting static diameters. In view of the large potential benefits of optimization of the 
matching of patients and access type, further and larger studies of novel techniques are urgently 
needed. 
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Abstract
Background. The autologous AV-fistula is the vascular access of choice in hemodialysis patients 
because of superior long-term survival due to a lower risk for thrombosis and infection. Access 
surgery should be followed by adequate  fistula  maturation,  i.e.,  a  gradual  increase  of  vessel 
diameter, and thus increase in access flow. We hypothesized that preoperative measurement of 
the arterial forearm blood flow (FBF) reserve predicts successful fistula development. 
Methods and patients. Prior to surgery, we measured FBF during incremental infusion of both an 
endothelium-dependent  vasodilator,  metacholine  (MCh),  and  an  endothelium-independent 
vasodilator, sodium nitroprusside (SNP), using venous occlusion plethysmography. Twenty-one 
patients (age 62 3, (mean sem), 10M /11F) with end-stage renal failure awaiting access surgery 
were studied. 
Results. In patients with successful AVF maturation (n=17) the AUC of both vasodilators was 
higher than in patients with AVF failure (n=4)(MCh: 122.2 9.8 U vs. 79.1 5.8, p<0.05; SNP: 
255.9 19.4 vs. 127.8 29.4, p<0.01). The absolute FBF increase was also significantly different 
between both groups (MCh:10.3 0.9 vs. 6.2 1.0 mL/100mL/min, p=0.03; SNP: 11.8 1.1 vs. 5.4
1.4 mL/100mL/min, p<0.01). No AVF failure was observed when AUC was above 100 U after 
MCh (n=11) (p<0.05),  or when AUC was above 200 U after SNP (n=13) (p<0.01).  Baseline 
MAP and FBF was not different (107 4 vs. 109 5 mmHg, N.S.; 3.4 0.7 vs.4.6 0.4, N.S.). Duplex 
radial  artery  diameter  did  not  differ  between  patients  with  successful  or  unsuccessful  AVF 
maturation (2.4 0.2 vs. 2.8 0.3, N.S.). 
Conclusions. We conclude that with measurement  of FBF reserve,  successful  or unsuccessful 
AVF maturation can be predicted accurately. Endothelial function does not seem to play a role, as 
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endothelium-dependent  and  -independent  vasodilators  had  similar  effects.  In  addition  to 
anatomical mapping, functional preoperative evaluation may improve AVF outcome.
Introduction
Adequate blood flow through an arterio-venous access is mandatory for successful hemodialysis 
in  patients  with  end-stage  renal  disease  (ESRD).  According  to  DOQI-guidelines,  the  native 
radiocephalic arterio-venous fistula (AVF) as described by Brescia and Cimino, is the access of 
first choice (1). Patency rates of AVF are clearly superior when compared to the outcome of 
arterio-venous grafts (AVG), which is the result of much less thrombotic and infectious events in 
AVF. However, it is known that up to 15% of all newly created AVF fail shortly after surgery as 
a result of thrombosis. These so called early failures are frequently regarded as technical errors, 
although several hemodynamic parameters may also play a role. 
After creation of an AVF for hemodialysis, blood flow through the radial artery will increase as a 
result of vasodilatation and vascular remodeling. Girerd et al. found a 1.4 fold increase in arterial 
diameter while the intima media thickness remained unchanged, clearly suggesting a remodeling 
of the arterial wall (2). This adaptive response appears to be crucial in reducing wall shear stress 
to baseline values. Major calcification and stiffening of the radial artery wall will inhibit proper 
vasodilatation, which will  lead to inadequate  arterial  inflow of the AVF. Vasodilatation after 
AVF-creation is primarily caused by acute release of nitric oxide by endothelial cells, so-called 
endothelium-dependent  vasodilatation.  Also,  endothelial  cells  play  a  central  role  in  vascular 
remodeling. This is illustrated by the observation that endothelial denudation and inhibition of 
NO by L-NAME abolish arterial enlargement in animal models of arterio-venous fistula (3-5). 
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Endothelium-dependent  vasodilatation  of  forearm  capacitance  vessels  is  affected  by  many 
diseases, among which several are known to cause renal failure, like diabetes and hypertension 
(6).  Also,  in  patients  with  different  stages  of  renal  failure  defective  endothelial  vasodilator 
function has been demonstrated (7). 
We hypothesized that the forearm blood flow reserve, i.e. the increase of forearm blood flow as a 
result  of  vasodilatation,  is  an  important  determinant  of  failure  of  newly  created  AVF  in 
hemodialysis patients. Therefore, we determined whether forearm blood flow reserve in patients 
with end-stage renal failure awaiting vascular access surgery, was predictive of early failure. To 
discriminate  the  influence  of  the  endothelium  in  early  fistula  failure,  we  measured  both, 
endothelium  dependent  and  endothelium  independent  forearm  vasodilatation,  using  forearm 
venous occlusion plethysmography. Duplex radial artery diameter will be evaluated in order to 
find  any  relationship  between  functional  and  anatomical  data.  Furthermore,  the  number  of 
surgical or percutaneous procedures needed to obtain a functional AVF was determined.
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Subjects and methods
Subjects
Patients with end-stage renal disease (ESRD) requiring hemodialysis and awaiting AVF creation 
were included after written informed consent. The trial protocol was approved by the institute’s 
Medical Ethics Committee. Based on physical examination and preoperatively determined duplex 
parameters,  the vascular surgeon decided the feasibility of creating an AVF in the individual 
patient. Patients with no visible and/or a tortuous short cephalic vein and/or radial artery diameter 
less than 1.5 mm received an AVG and did not participate in the study. The patients were asked 
to refrain from smoking and caffeine or alcohol containing beverages for at least 12 hours prior to 
the study. All vasoactive medication was discontinued 7 days before the study. Within one month 
after  Duplex  ultrasonography  and  forearm strain  gauge  plethysmography  patients  underwent 
vascular access surgery. 
AVF  which  could  be  used  for  successful  two  needle  hemodialysis,  judged  by  a  panel  of 
experienced dialysis nurses who were unaware of the results of all additional forearm studies, 
were defined as functional AVF. Successful dialysis was defined as the ability to provide at least 
250  mL/min  dialyzer  pump  flow.  After  surgery,  all  patients  received  anticoagulant  therapy 
(acenocoumarol) for six months.
Methods
Duplex ultrasonography
Pre-operative  duplex  scanning  of  the  upper  extremity  was  performed  with  the  HDI  3000 
Ultrasound System (ATL Ultrasound Bothell, USA). A 2-D linear electronic probe, pulse wave 
Doppler and color wave Doppler at 5.0 MHz were used. The internal diameter of the radial artery 
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at the wrist was measured using M-mode technique. A tourniquet to increase vascular size was 
not used. The patency of both the proximal cephalic and subclavian vein was examined. 
Four  weeks  after  surgery  Duplex  ultrasonography  was  performed  to  examine  the  AVF  for 
development of stenotic lesions. Patients with significant stenotic lesions (>50% of the luminal 
diameter) were referred for percutaneous transluminal angioplasty within 2 weeks.
Forearm strain-gauge plethysmography
Venous occlusion strain-gauge plethysmography is a frequently used technique for measurement 
of forearm blood flow and venous compliance (8). Throughout the years the method has been 
standardized and computerized, resulting in a reasonably simple and reliable technique (9-11). It 
works on the principle that during short-term occlusion of venous return, the rate of distension of 
the forearm is proportional to the rate of arterial inflow into the forearm. Provided that the arterial 
blood pressure remains constant, changes in flow reflect changes in smooth muscle tone in small 
arteries and arterioles. 
The  experiments  were  performed  in  the  afternoon  in  quiet  air-conditioned  room at  constant 
temperature  (20-24ºC).  Subjects  were studied in supine  position  with arms supported 10 cm 
above the level of the right atrium. The arm chosen for vascular access surgery, which was the 
non-dominant arm in the majority of subjects, was used for measurements. Forearm volume was 
measured by water displacement. The brachial artery was cannulated (cannula of 1.0 × 45 mm) 
after  local  anesthesia  with  lidocaine  (1%).  A mercury-in-silastic  strain gauge was  positioned 
around the widest  part  of the forearm. The strain gauge was connected to a  plethysmograph 
(model  periflow  SU  4,  Janssen  Scientific  Instruments,  Beerse,  Belgium)  with  electronic 
calibration for percentual volume changes and a built-in flow integrator module. To enable off-
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line data analysis, the plethysmograph was connected to an A/D converter (Dataq Instruments, 
model DI 420, Akron, OH, USA) for electronic data storage. A venous occlusion cuff was placed 
around the upper arm. Inflation was achieved using an ECG-triggered rapid cuff inflator (Janssen 
Scientific Instruments), inflating the cuff to 60 mmHg during 4 heartbeats and deflating it during 
the next 3 heartbeats. 
Baseline FBF (mL /100ml forearm/min) (FBFBL) was measured after a resting period of at least 
30 minutes after intra-arterial cannulation of the brachial artery. During this measurement saline 
was infused at 1 mL/min.  Then, FBF was measured during incremental infusions (dose range 
0.1-10  µg/kg/min)  of  metacholine  (MCh),  to  examine  endothelium-dependent  vasodilatation. 
Each dosing step lasted 4 minutes. Sodium nitroprusside (SNP) was used (dose range 1-20  µ
g/kg/min) at 4-minute dosing steps to examine endothelium-independent vasodilatation. Between 
the various experiments sufficient time was allowed for FBF to return to baseline levels. Mean 
arterial blood pressure (MAP) and heart rate were measured continuously using the Finapress 
blood pressure monitor (Ohmeda, Inglewood, CO, USA). 
Statistical analysis
Results are given as means±S.E.M. Dose-response curves were constructed for the vasodilator 
effects of MCh and SNP. Absolute change in FBF (dFBFABS), area under curve (AUC) for MCh 
and  SNP  and  Duplex  radial  artery  diameter  were  compared  in  patients  with  and  without 
functional  AVF,  using  Students’  t-tests.  P-values  below  0.05  were  considered  statistically 
significant.
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Results
Twenty-one  consecutive  patients  with  ESRD awaiting  AVF creation  were  included  into  the 
study. All patients received an brachio-cephalic forearm fistula. In 4 patients the AVF occluded 
(AVF-NF), 3 of which in the first week after surgery. The remaining 17 AVF matured enough to 
enable 2-needle dialysis, and were functional after 78±11 days (range 43-157, AVF-F). Six AVF 
developed one or more significant stenotic lesions. Most lesions (6/11) were found in the venous 
outflow tract of the AVF, 3 were located at the anastomosis and the other 2 were arterial stenoses. 
After  percutaneous  transluminal  angioplasty  these  AVF  matured  and  were  successfully 
cannulated  for  hemodialysis.  The  remaining  11  patients  had  a  functional  AVF within  eight 
weeks.  Duplex  ultrasonography 4  weeks  after  surgery could  not  demonstrate  any significant 
stenoses. Patient characteristics are depicted in Table 1.
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Table 1. Patient characteristics
AVF (n=21)
AVF-F AVF-NF
n=17 n=4
Age 63±3 57±5
Gender (m/f) 8/9 2/2
Creatinin (µmol/L) 658±53 563±47
Diabetes (n) 8 0
Hypertension (n) 16 3
Smoking (n) 4 1
Cardiovascular disease (n)* 6 2
*stroke, peripheral vascular disease and/or  myocardial infarction
FBF venous occlusion plethysmography
Baseline  mean  arterial  blood  pressure  (MAPBL)  -measured  30  minutes  after  intra-arterial 
cannulation-  was  107±4  mmHg,  and  remained  stable  throughout  both  infusion  protocols 
(MAPMCh 109±5 mmHg and MAPNP 107±4 mmHg, N.s, paired t-test.). Considering all patients 
(n=21), AUC after MCh infusion was significantly lower than AUC after NP infusion (114.0±8.8 
and  231.5±19.9  resp.,  p<0.0001,  paired  t-test).  Also,  the  absolute  increase  in  FBF  differed 
between both infusion protocols:  dFBF MCh was 9.1±0.8 mL/100mL/min and dFBF NP was 
10.5±1.1 mL/100mL/min, p=0.04, paired t-test).
FBFBL was 4.4±0.4 mL/100mL/min and did not differ between AVF-F and AVF-NF (4.6±0.4 
mL/100mL/min and 3.4±0.7, p=0.2). 
MCh
 In patients with non-functional AVF (AVF-NF) the absolute change in FBF (dFBFABS) during 
MCh infusion was 6.2±1.0 mL/100mL/min. In patients with functional AVF (AVF-F) dFBFABS 
was more prominent:  10.3±0.9 mL/100mL/min (p=0.03).  The AUC was 122.2±9.8 in AVF-F 
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patients and 79.1±5.8 in AVF-NF patients (p=0.045). Furthermore, all 4 failures had dFBFABS and 
AUC  values  lower  than  the  average  dFBFABS and  AUC  values  of  the  whole  series  (9.1 
mL/100mL/min and 114 respectively,  Figure 1.).  No fistula failure was seen in patients with 
dFBF ABS  ≥ 10 mL/100mL/min (0/9). Four failures occurred in 12 patients with dFBF ABS < 10 
mL/100mL/min. This difference was insignificant by Fisher’s exact test (p=0.1). It is noteworthy 
that all 4 fistula failures occurred in 10 patients with AUC < 100, while no failures were seen in 
11 patients with AUC ≥ 100. This difference was statistically significant by Fisher’s exact test 
(p=0.04).
NP
The dFBFABS during NP infusion was significantly higher in AVF-F than in AVF-NF patients 
(11.8±1.1 mL/100mL/min and 5.4±1.4, respectively, p=0.01). The AUC was 255.9±19.4 in AVF-
F and 127.8±29.4  in  AVF-NF patients  (p=0.008).  Again,  all  non-functional  AVF had lower 
dFBFABS and AUC than the averages of the total group (10.5 mL/100mL/min and 231.5, Figure 
1.). No differences in the risk of fistula failure were found between patients with dFBFABS <10 
and patients with dFBFABS ≥10 mL/100mL/min. Of 8 patients with AUC  <200, 50% of AVF 
failed, while none of the AVF of patients with AUC ≥200 failed (13/13), which was a significant 
difference (p=0.01, Fisher’s exact test).
Duplex radial artery diameter
No significant differences were found between radial artery diameter of patients with AVF-F and 
AVF-NF  (2.4±0.2  and  2.8±0.3  mm,  respectively,  p=0.2).  Interestingly,  all  4  non-functional 
fistulae had radial artery diameters of at least 2.2 mm.
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Discussion
Under  ideal  circumstances,  in  which  a  group of  skilled  vascular  surgeons  is  responsible  for 
vascular  access  surgery,  the  success  of  a  newly  constructed  AVF  must  depend  on  several 
hemodynamic variables affecting the in- and outflow of the AVF. Since AVF construction is 
directly followed by increased arterial  blood flow, hypothetically,  higher  forearm blood flow 
capacitance,  should be associated with better  outcome of AVF. To provide evidence for this 
hypothesis,  we  measured  forearm  blood  flow  changes  after  infusion  of  the  vasodilatant 
substances MCh and SNP, using venous occlusion plethysmography. To our knowledge, this is 
the first time invasively measured forearm blood flow capacity is related to outcome of AVF. 
This  study shows that  pre-operative forearm blood flow capacity  is  predictive of early  AVF 
failure.  Furthermore,  our  data  indicate  that  AVF failure  is  not  the  result  of  pure endothelial 
dysfunction, because endothelial-independent forearm blood flow capacity is also diminished in 
patients with AVF failure. Finally, we showed that arterial diameter is not predictive of early 
AVF failure.
We  demonstrated  that  patients  with  insufficient  forearm  blood  flow  capacity  are  likely  to 
encounter primary AVF failure. Especially, the AUC of dose response curves seems predictive of 
AVF outcome.  An AUC of 100 in MCh and 200 in NP seems a prerequisite of short  term 
success of the AVF. To our knowledge forearm blood flow capacity using venous occlusion 
plethysmography was never examined as a determinant of fistula failure. However, Malovr et al. 
demonstrated a significantly lower arterial blood flow increase and higher vascular resistance 
after reactive hyperemia after reopening a clenched fist in patients with nonfunctional AVF in 
compare  to  patients  with  functional  AVF (12,13).  In  agreement  with  Yerdel  et  al.,  baseline 
forearm blood (14)  did  not  differ  between  patients  with  functional  and not-functional  AVF. 
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Therefore, differences in concentration of drug reaching the tissues, influencing the response to 
it, can be neglected. 
We also hypothesized that the endothelium, responsible for direct nitric oxide release after AVF 
construction,  is  of  importance  in  immediate  AVF  failure.  Our  data  indeed  demonstrate 
disturbance  of  MCh  induced  vasodilatation  with  relative  preservation  of  NP  induced 
vasodilatation, indicating endothelial dysfunction in ESRD. However, both determinants (AUC 
MCh and AUC NP) were found to be predictive of immediate AVF failure, suggesting structural 
arterial  wall  changes  besides  endothelial  dysfunction.  Indeed,  in  a  recent  study preoperative 
Duplex evaluation demonstrated severe arterial wall changes – wall thickening and calcification- 
in  almost  40% of  all  patients  awaiting  vascular  access  surgery  (13).  Since  our  patients  are 
comparable with respect to severity of renal dysfunction, it is reasonable to believe that these 
structural changes are also of importance in our study population.
In the past,  several studies demonstrated worse AVF outcome in women and elderly (15-17). 
Because of small numbers, our data do not allow multivariate analysis of these clinical variables, 
but  we  found  no  differences  in  age  and  gender  between  patients  with  functional  and  non-
functional AVF. It is possible that our study design, which selected patients with a radial artery 
diameter less than 1.5 mm for AVG, has eliminated mostly women and elderly from the study. 
However, within the group with functional AVF, almost 90% of interventions for stenotic lesions 
took place in women older than 65 years. 
With the advent of mercury-in- rubber strain gauges, the technique of forearm venous occlusion 
plethysmography is accurate and widely used to probe mechanisms of human vascular control 
Venous occlusion plethysmography has the advantage of measurement of  total forearm blood 
flow. However, clinical implementation of venous occlusion plethysmography,  prior to access 
surgery, is not simple. First, this technique is very time-consuming and requires expensive hard- 
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and software. Second, and even more important,  it  is an invasive measurement.  Although we 
didn’t encounter any complications in our study, theoretically,  formation of haematoma could 
interfere with arterial inflow. In vessels with relatively small diameter, such as the radial artery, 
estimation  of  volume  flow  by  duplex  sonography,  using  cross-sectional  area,  is  inherently 
inaccurate.  However,  Malovr  et  al.  described an alternative  approach to measure  blood flow 
capacitance in the radial artery (12). After releasing a fist the triphasic Doppler waveform in the 
radial artery should normally change to a low-resistance biphasic waveform, caused by post-
ischemic dilatation of peripheral arterioles and consecutive reduction of peripheral  resistance. 
Patients  who lacked  this  conversion  showed significantly  more  AVF failure.  It  would be  of 
interest  to  study  both  techniques  within  one  patient  to  determine  the  correlation  of  both 
modalities.
Although  the  number  of  patients  is  small,  necessitating  further  prospective  trials,  our  study 
provides valuable information on the influence of arterial inflow capacitance on fistula failure. Of 
course,  arterial  inflow  is  not  the  only  factor  in  fistula  maturation,  and  always  depends  on 
sufficient outflow as well. Considering the amount of stenoses found in the outflow tract at post-
operative  Duplex-examination,  it  is  possible  that  inappropriate  venous distensibility  is  of 
importance  in the maturation  of  AVF that  survive  the first  period after  surgery.  Ideally,  the 
measurement of pre-operative forearm blood flow capacitance may direct the operation to be 
performed under more suitable conditions, or may result in primary placement of graft material, 
in order to overcome fistula failure in patients with unsuitable vascular anatomy.  In order to use 
our findings in daily clinical practice, future studies should focus on easier, non-invasive ways to 
examine the role of forearm blood flow capacity in early fistula failure.
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Abstract
Background. Increased venous pressure (VP) and decreased access flow (Qa) are predictors of 
dialysis access graft thrombosis. VP is easily obtainable. Qa assessment requires a special device 
and takes more time. Aims of our randomized multi-center studies were to compare outcome in 
patients with grafts monitored by VP or Qa (study A) or monitored by VP or the combination of 
VP and Qa (study B). 
Methods. We performed VP measurements that consisted of weekly VP at a pumpflow of 200 
mL/min (VP200) and the ratio of VP0/MAP. Qa was measured every 8 weeks with the Transonic 
HD01 hemodialysis  monitor.  Threshold levels for referral for angiography were VP200 >150 
mmHg  or  VP0/MAP  >0.5  (both  at  3  consecutive  dialysis  sessions),  or  Qa  <600  mL/min. 
Subsequent therapy consisted of either PTA or surgery. 
Results. Total follow-up was 80.5 patient-years for 125 grafts. The vast majority of a total of 131 
positive tests was followed by angiography and corrective intervention. In study A, the rate of 
thromboses not preceded by a positive test was 0.19 and 0.24 per patient-year (P = NS) and in 
study B it was 0.32 versus 0.28 per patient-year (P = NS). Survival curves were not significantly 
different between the subgroups. 
Conclusions. These data demonstrate  that standardized monitoring of either VP or Qa or the 
combination of both and subsequent corrective intervention can reduce thrombosis rate in grafts 
to below the recommended quality of care standard (i.e. 0.5 per patient-year, NKF-DOQI). These 
surveillance strategies are equally effective in reducing thrombosis rates.
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Introduction
Thrombosis  remains  a  major  problem  in  vascular  access  for  hemodialysis,  particularly  in 
polytetrafluoroethylene (PTFE) grafts. It accounts for considerable morbidity and mortality with 
an annual cost of close to $1 billion in the United States and is responsible for 17-25% of all 
hospitalizations in dialysis patients (1-3).
Thrombosis occurs at a rate of 0.5 to 2.5 events per patient-year (4-8). In most cases thrombosis 
is associated with the presence of stenoses at the venous anastomosis or in the outflow tract (9-
13). Stenosis increases resistance over the flow tract. Because the graft has no autoregulating 
capacities,  blood flow (Qa) drops and venous pressures (VP) rise. These variables have been 
shown to predict  thrombosis. More importantly, several studies demonstrated that referral for 
corrective intervention based on these parameters can prevent thrombosis (14-18). 
We and others confirmed that patients with outflow stenosis have on average a higher VP and/or 
lower Qa (14,19). However, VP did not correlate with Qa. In other words not all patients with 
high VP had low Qa,  indicating  that  not  all  patients  who are  at  risk  for  thrombosis  can be 
identified by VP measurements. We also showed that inflow resistance (that is resistance of the 
flow tract upstream of the venous needle) comprises a substantial and very variable part of total 
graft resistance. Indeed, several studies have indicated that in up to 29% of thrombosis cases, 
stenoses may be located in the arterial part of the graft (13, 20-23). The inflow resistance is not 
reflected  by  VP  measurements,  whereas  Qa  measurements  are  a  reflection  of  total  graft 
resistance.  This  could  make  VP less  effective  as  selection  parameter  for  patients  at  risk  for 
thrombosis  than  Qa.  In  contrast  to  Qa  measurements,  VP  can  be  measured  by  the  dialysis 
machine, is easy to obtain and requires little time investment. Furthermore, some studies have 
convincingly indicated that the use of VP measurements as a selection variable for diagnostic and 
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subsequent  corrective procedures,  results  in  thrombosis rates between 0.2 and 0.4 events per 
patient-year  (6,14,16).  Although we provided the theoretical  basis  that  Qa measurements  are 
better than VP measurements, the question is whether Qa measurements really confer additional 
benefit in patients who are monitored by VP. In other words, when simple clinical variables such 
as VP are used, is there any additional benefit when periodic Qa measurements are added to the 
surveillance protocol?
Our hypothesis  for the present  studies  was as  follows: Qa measurements  are  better  than VP 
measurements in identifying patients at risk for thrombosis. As a consequence: referral of patients 
for corrective interventions based on Qa measurements alone or on the combination of VP and 
Qa reduces thrombosis rate more than referral based on VP alone.
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Methods
Patients
Five dialysis centers participated in this study. All patients with a hemodialysis access PTFE graft 
were eligible to enter into the study. Exclusion criteria were inability to give informed consent 
and contrast allergy. 
Studies were approved by the Institutional Ethical Review Committees. Informed consent was 
obtained from all patients.
Surveillance protocols
Two surveillance  studies  were conducted concurrently.  In  study A patients  were assigned  to 
weekly VP measurements (Group A1) or periodic Qa measurements (Group A2). In study B, 
patients  were  assigned  to  weekly  VP  measurements  (Group  B1)  or  the  combination  of  VP 
measurements and periodic Qa measurements (Group A2). Study A was instituted in one center 
(Rotterdam)  and  study B in  four.  Within  the  centers  the  patients  were  prospectively  and  at 
random allocated to one of the subgroups of each study (Fig. 1). 
Venous pressure monitoring
Measurements were done once weekly, within the first half-hour of dialysis, and included both 
dynamic  and  static  VP  measurements.  When  one  or  both  measurements  were  positive  (see 
Indication for referral for angiography), measurements were repeated the next dialysis session. 
All centers had dialysis machines with digital pressure displays. Maintenance and calibration was 
done according to the manufacturer’s  recommendations on a regular basis  by an experienced 
technician. 
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Dynamic venous pressure
Digitally  displayed  dynamic  VPs  were  assessed  with  a  fixed pump flow set  at  200 mL/min 
(VP200), as described by Schwab et al (16). Ten subsequent readings on the dialyzer display 
were averaged. After the measurement the pump flow was set to the original level.
Static venous pressure
Static VP (VP0) was assessed with zero pump flow with the tubing out of the air lock in order to 
avoid automatic closure of the tubing after the pump was shut off. VP0 was divided by mean 
arterial pressure (MAP) to correct for blood pressure differences as described by Besarab et al 
(14). No correction for height differences was made. MAP was calculated by taking two times 
diastolic pressure plus systolic pressure divided by three.
Access flow measurement
Measurements were done every eight weeks. Qa was measured with the Transonic Hemodialysis 
Monitor (Transonic Systems Inc, Ithaca, NY). The theoretical background, bench validation and 
in vivo validation are described in detail in previous papers (24,25). Periodic calibration was 
done by the local distributor.  Qa determination consisted of the average of three consecutive 
measurements. If Qa levels reached between 600 and 800 mL/min the measurement was repeated 
after  one month.  All  measurements  were done with a dialyzer  blood flow of more than 200 
mL/min. 
Indication for referral for angiography
Referral of Group A1 patients for angiography was based on three consecutive dialysis sessions 
with elevated static and/or dynamic VP. Patients in Group A2 underwent angiography when Qa 
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fell  below 600 mL/min.  Indication for referral  of Group B1 patients  for angiography was an 
elevated static and/or dynamic VP, similar to Group A1. In Group B2 an elevated static and/or 
dynamic VP and/or Qa below 600 mL/min were reasons for referral. The threshold level for the 
static VP ratio was 0.5, according to the method described by Besarab et al [14]. Threshold for 
dynamic VP was 150 mmHg.
Angiography was done to determine presence and location of the stenosis. If a stenosis of >50% 
was present, the primary choice of treatment was percutaneous transluminal angioplasty (PTA). 
After an intervention patients continued the same surveillance mode as before. All thrombotic 
events and interventions (elective or therapeutic) were recorded.
Data analysis
Thrombosis-free survival rates between the subgroups in both groups were tested with the log 
rank  test.  Curves  were  made  with  Kaplan-Meier  survival  analysis  showing  event-free  graft 
survival. An event was defined as a thrombotic event without a preceding positive test, either VP 
(Group  A1,  B1 and B2)  or  Qa  (Group A2 and B2).  Differences  between incidence  rates  of 
thrombosis and of intervention were calculated with Poisson regression analysis. A  P value of 
less than 0.05 was considered significant.
Power analysis 
For calculation of group sizes we made the following assumptions. Our historical thrombosis rate 
was 1.2 event  per  patient-year  (7),  but  improved after  intensifying  access  surveillance  using 
dynamic VP measurements to approximately 0.85. At that time however, no specific surveillance 
protocol was used. We expected the thrombosis rate in the Qa groups to be lower than in the VP 
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groups based on considerations described in the Introduction. We calculated that with a follow-up 
of 100 patient-year a thrombosis rate difference of 0.25 could be demonstrated (α = 0.05,  β = 
0.20). Obviously, for differences greater than 0.25 less follow-up is needed.
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Results
Data were evaluated after a follow-up of approximately two times 40 patient-years. An interim 
analysis  showed that  results  in  VP monitored  grafts  were much better  than anticipated.  This 
justified  the  conclusion  that  continuation  of  the  study  was  not  likely  to  result  in  clinically 
significant differences. 
Patient characteristics
Study A included 53 PTFE grafts (51 patients). Twenty-five grafts were monitored by VP (Group 
A1) and 28 grafts by Qa measurements (Group A2). Study B included 72 grafts (68 patients). 
Thirty-one grafts were assigned to Group B1 (VP) and 41 grafts to Group B2 (VP + Qa) (Fig. 1).
In study A 19 patients were lost during follow up (8 in Group A1, 11 in Group A2). Reasons 
included death or abstinence of dialysis therapy (n=12), transplantation (n=3), refusal of further 
graft monitoring (n=2), change to peritoneal dialysis (n=1) or to another center (n=1). In study B 
15 patients were lost to follow-up (8 in Group B1, 7 in Group B2). Reasons were death (n=8), 
transplantation  (n=4),  abstinence  of  dialysis  therapy (n=1),  and change to  peritoneal  dialysis 
(n=2).
Demographic  patient  characteristics  for  both studies  are  depicted  in Table  1.  There  were  no 
significant differences in age, percentage diabetics,  race, or time on hemodialysis  therapy, in 
either study A or B. 
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Table 1. Patient characteristics 
Study A Study B
VP (A1) Qa (A2) P VP (B1) VP + Qa (B2) P
Patients 24 27 NS 31 37 NS
Median age years (range) 65(26-86) 66(21-84)
Mean age years (SD) 61 (17) 61 (18) NS
65(19-80) 61(21-87)
62 (14) 60 (17) NS
Gender
male 9 18 0.04 15 16 NS
female 15 9 16 21
Cause of renal failure
diabetes 4 (16%) 7 (26%) NS 8 (26%) 4 (11%) NS
hypertension 8 8 2 2
glomerulonephritis 3 2 3 2
polycystic kidney disease 3 0 0 5
other 4 7 13 19
unknown 2 3 5 5
Race
Caucasian 18 (75%) 23 (85%) NS 30 (97%) 30 (81%) NS
black 5 4 0 4
Asian 1 0 1 3
Median HD therapy  months 
(range)
18.1
(2.3-88.8)
13.9
(0.9-116.7)
Mean  HD  therapy  months 
(SD)
27.9 (26.9) 22.6 (28.2) NS
22.0
(0.0-281.0)
24.8
(0.2-302.1)
43.9 (58.2) 44.3 (69.6) NS
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Outcome
Study A
Total  follow up was  37.8  patient-years.  Graft  monitoring  resulted  59  times  in  positive  tests 
followed by 55 angiograms, which subsequently resulted in 48 PTA procedures and 7 surgical 
interventions. Table 2 shows which test(s) led to these interventions. In all cases of Group A1 it 
was an increased VP0/MAP, which led to the intervention. In the vast majority of angiograms 
venous stenoses were present (Table 3). Graft characteristics and outcomes of individual patient 
groups are outlined in Table 4 and 5.
Table 2. Which positive test led to intervention?
Study A Study B
VP (A1) Qa (A2) VP (B1) VP + Qa (B2)
VP0/MAP 15 - 12 6
VP200 0 - 4 0
VP0/MAP + VP200a 15 - 9 8
Qa - 25 - 3
Qa +VPb - - - 13
Total (PTA) 30 (26) 25 (22) 25 (23) 30 (26)
a both tests were positive
b VP means either a positive VP0/MAP, or a positive VP200, or both
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Table 3. Localization of stenotic lesions in grafts of patients referred for PTA
Study A Study B
VP (A1) Qa (A2) VP(B1) VP + Qa (B2)
Localization
Venous graft +/- outflowa 24 (92%) 19 (86%) 22 (96%) 20 (77%)
Arterial graftb 0 (0%) 1 (5%) 0 (0%) 1 (4%)
Venous + arterial graftc 2 (8%) 2 (9%) 1 (4%) 5 (19%)
Total PTA 26 22 23 26
a stenosis at or near the venous anastomosis and/or in the venous outflow tract
b stenosis at or near the arterial anastomosis
c combination of  a and  b, i.e. a stenosis at or near the venous anastomosis and/or in the venous 
outflow tract and a stenosis at or near the arterial anastomosis
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Table 4. Graft characteristics
Study A Study B
VP (A1) Qa (A2) P VP(B1) VP+Qa (B2) P
Grafts 25 28 31 41
Median  age  graft 
months (range)
6.7
(1.0-49.7)
4.6
(1.2-28.4)
Mean age graft  months 
(SD)
12.8 (13.8) 8.3 (7.6) NS
11.6
(0.0-73.6)
6.0
(0.0-100.0)
18.1 (20.9) 16.4 (24.8) NS
Configuration graft
looped, forearm 23 26 NS 31 37 NS
straight, upperarm 2 2 0 4
Anticoagulant therapy
acenocoumerol 14 15 20 23
aspirin 5 2 3 5
combination 1 0 2 0
none 5 11 6 13
Follow-up
patient-years 21.3 16.5
median  months 
(range)
11.2(0.9-15.5) 5.8(1.1-15.2)
mean months (SD) 10.4 (4.4) 7.2 (4.9)
0.016
21.6 21.1
5.9(1.7-20.4) 5.1(0.4-20.4)
8.4 (5.7) 6.2 (4.9) NS
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During the follow-up, 12 thrombotic events occurred (6 in each patient group), resulting in a 
thrombosis frequency of 0.31 per patient-year. In both subgroups thrombosis was predicted by a 
positive test (VP or Qa) in 2 occasions, but thrombosis occurred pending the angiography (2 – 15 
days after obtaining positive tests). In 8 grafts thrombosis was not preceded by an abnormal VP 
or flow, which resulted in an unpredicted thrombosis rate of 0.19 and 0.24 per patient-year (P = 
NS).  No  anatomical  information  is  available  from  these  8  grafts  with  thrombosis.  Reasons 
included:  no attempt  to  reestablish  patency or  surgical  thrombectomy without  intra-operative 
angiography.   
Kaplan-Meier survival curves did not show a significant difference between the subgroups (Table 
5, Fig. 2). The 6 months event-free survival (an event equals thrombosis not predicted by the test) 
was 87% for the VP group, and 84% for the Qa group (P = NS).
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Table 5. Results
Study A Study B
VP (A1) Qa (A2) P VP (B1) VP+Qa (B2) P
Interventions/ pt.-yr. (n pts) 1.41 (17) 1.52 (11) 1.16 (16) 1.42 (20)
balloon angioplasty (n) 26 22 23 26
surgical (n) 4 3 2 4
Thromboses total (n pts) 6(4) 6(4) 12(10) 18(16)
predicted / unpredicted 2/4 2/4 5/7 12/6
Unpredicted  thromboses/ 
pt.-yr.
0.19 0.24 NS 0.32 0.28 NS
6  mnth.  event-freea surv. 
rate (%)
87 84 NS 85 88 NS
12  mnth.  event-freea surv. 
rate (%)
77 84 NS 85 80 NS
a an event is defined as an unpredicted thrombosis
Study B
The total follow up period was 42.7 patient-years. Graft monitoring resulted 72 times in positive 
tests  followed by  55  angiograms,  which  subsequently  resulted  in  49  PTA procedures  and 6 
surgical interventions. Table 2 shows which positive test(s) led to an intervention. In 90% of 
cases there was an elevated VP0/MAP. Venous stenosis (at or near the venous anastomosis or in 
the venous outflow tract) was present in 98% of the grafts treated with PTA (see Table 3). Graft 
characteristics and outcomes of individual patient groups are outlined in Table 4 and 5.
Thirty thrombotic events occurred (12 in the VP group, 18 in the VP + Qa  group), that is 0.7 per 
patient-year. Five out of the 12 thrombosis in the Group B1 were preceded by a positive test, but 
thrombosis occurred after 2 – 15 days pending the angiography. In all five cases thrombectomy 
was done and a venous stenosis was found. In Group B2, 12 out of 18 thromboses were predicted 
by one or more positive tests.  In 7 cases thrombosis occurred after 3 – 20 days pending the 
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angiography (all of these seven grafts showed a venous stenosis after thrombectomy), and in 5 
cases  intervention  was  not  done  for  various  reasons,  including  graft  infection,  poor  clinical 
condition and switch to peritoneal dialysis. In 13 cases thrombosis was not preceded by a positive 
test, resulting in a thrombosis frequency of 0.32 (Group B1) and 0.28 (Group B2) (P = NS). Ten 
of these 13 thromboses were treated by radiological thrombolysis.  Stenoses were found at the 
venous anastomosis (n=5, Group B1; n=3, Group B2), at the arterial anastomosis (n=1, Group 
B2), or at both anastomoses (n=1, Group B2). In 3 grafts it was impossible to obtain anatomical 
information, because no attempt was made to reestablish patency. 
Kaplan-Meier survival curves did not show a significant difference between the subgroups (Table 
5, Fig. 3). The 6 months event-free survival (an event equals thrombosis not predicted by the test) 
was 85% for the VP group, and 88% for the VP + Qa group (P = NS). 
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Discussion
This  randomized,  prospective  multi-center  trial  allows  a  number  of  important  conclusions. 
Firstly,  we  confirm  that  thrombosis  rates  in  patients  monitored  and  selected  for  corrective 
interventions  based  on  VP  or  Qa  can  be  maintained  below  the  quality  of  care  standards 
formulated by the NKF-DOQI committee (4). Secondly, we show that thrombosis rates in groups 
monitored by VP or Qa alone or by the combination of tests do not differ. Thirdly, only a small 
minority  of  patients  was selected for  corrective interventions by Qa alone in the  group with 
combined  monitoring  of  VP  and  Qa.  Fourthly,  after  obtaining  abnormal  tests  subsequent 
diagnostic and interventional procedures should be instituted on short notice. It seems likely that 
the number of thromboses during the waiting time can be reduced. Finally, we confirm that static 
VP is more effective than dynamic VP for monitoring dialysis grafts.
The present study confirms the usefulness of VP and Qa measurements as access surveillance 
variables.  Previously,  we  have  presented  the  theoretical  basis  for  the  assumption  that  Qa 
measurements are better than VP (i.e. dynamic) measurements as a monitoring tool (summarized 
in (26)). This is based on the fact that some stenoses are located in the arterial flow tract that is 
upstream  of  the  venous  needle.  These  lesions  increase  resistance  and  reduce  Qa  without 
increasing VP, possibly even decreasing VP. Several studies have indicated that arterial stenoses 
occur  in  up  to  29%  of  thrombosis  cases  (20-23).  In  the  present  study,  we  found  a  strong 
predominance of venous lesions in the patients referred for angiography. In some patients having 
a graft  thrombosis without a preceding positive test,  thrombectomy was done. Also, in those 
patients venous lesions were more likely than arterial lesions. 
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Qa measurements have already been recognized as the preferred monitoring tool for vascular 
access  surveillance  (4,27).  However,  these  recommendations  are  primarily  based  on  clinical 
studies with a non-randomized or observational setup (19,25,28-30). To our knowledge, only one 
study  compared  Qa  with  static  VP  as  surveillance  variable.  Sands  et  al  (8)  showed  that 
intervention based on monthly Qa measurement or on monthly static VP measurements reduced 
thrombosis  rates  in  comparison  with  non-monitored  controls.  Some  important  differences 
between the two studies exist. The present study also includes a program combining VP and Qa. 
Theoretically, this combination is likely to be the most effective program (18). Furthermore, the 
study population of Sands et al consisted predominantly of AV fistulae (almost two-third in the 
control  and monitored  groups)  which  are  less  likely  to  clot.  Also,  threshold  for  referral  for 
angiogram (750 mL/min vs. 600 mL/min in our Qa groups),  and frequency of measurements 
(monthly VP vs. weekly in our VP groups) differed. There is some controversy about the optimal 
frequency. Some advocate the use of dynamic pressures weekly and static VP every two weeks 
(4), others suggest to measure dynamic VP every dialysis (27), or static VP every week (31). In 
the present study, we measured both dynamic and static VP once weekly during the same dialysis 
session.  Our  results  indicate  that  graft  surveillance  using  VP  or  Qa  measurements  strictly 
organized as in the present study results in identical thrombosis rates. This does not exclude the 
possibility that in patients who develop more arterial lesions for whatever reason, surveillance 
using Qa would result in lower thrombosis rates than using VP measurements.        
In our study most referrals for intervention in patients monitored by VP measurements alone 
(Group  A1  and  B1)  were  based  on  static  VP  measurements.  Although  dynamic  VP  was 
successfully used as part of an access surveillance program in some studies (6,11,16,32), there is 
convincing evidence that dynamic VP does not accurately reflect true intra-access pressure, and 
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therefore, does not reflect resistance caused by stenosis formation (14). Dynamic VP is highly 
biased  by  pump  flow,  blood  tubing,  needle  size,  and  blood  pressure  (33).  Static  VP 
measurements, on the other hand, particularly when corrected for mean arterial pressure, avoid 
these potential confounders.        
Also in Group B2 (combination of VP and Qa measurements) most referrals were based on VP 
and only  3  out  of  30  referrals  were  based  on  Qa alone.  These  data  indicate  that  when VP 
measurements are well organized, adding periodic Qa measurements is of limited value (Group 
B1 versus B2). On the other hand, study A clearly shows that when no VP measurements are 
done periodic Qa measurements result in identical thrombosis rates, proving the effectiveness of 
Qa as surveillance variable.     
In  this  study  21  of  the  42  thromboses  occurred  despite  preceding  positive  tests.  Sixteen 
thromboses occurred 2 to 20 days after obtaining the abnormal tests pending further diagnostic 
and correctional interventions. These results further support the idea that an increased VP and/or 
low Qa indeed predict imminent thrombosis. It seems likely that immediate institution of further 
treatment could have decreased the number of thromboses. 
The 21 thromboses, which were not preceded by positive tests, should not all be considered as 
failures  of  the  tests.  Flow  is  directly  related  to  blood  pressure.  Blood  pressure  may  show 
considerable variability in hemodialysis patients and is likely to reach its lowest levels in the first 
hours after the hemodialysis session and especially during the night (34). Therefore, it is possible 
that  flow is  adequate  at  the time measurements  are  done,  but reaches  levels  associated with 
thrombosis in the interdialytic period. 
Several issues need to be addressed with respect to the present study. 
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Firstly, our power calculations were based on the assumption that there would be a difference in 
thrombosis rates between VP and Qa monitored patients. However, the strict adherence to the 
surveillance  protocols  improved  our  results  using  VP  measurements  when  compared  to  our 
historic controls. Differences in the present study were not statistically significant. The results 
indicated that continuation of the study was not likely to result in clinically relevant differences. 
Secondly, we measured Qa every two months, but repeated the measurement after one month if 
Qa reached levels between 600 and 800 mL/min. This frequency was mainly based on feasibility 
considerations.  It  remains unclear,  whether  a higher frequency of Qa measurements,  as was 
suggested by others (8,27) would decrease the already low thrombosis rate further. Furthermore, 
we  can  not  exclude  the  possibility  that  decreasing  the  frequency  of  VP  measurements,  for 
instance every 2 weeks, as was suggested elsewhere (4), would result in identical results. 
Additionally, threshold levels for selection for referral may vary. We used a level of 600 mL/min 
as Qa threshold level for referral. We based our choice on earlier results (35) and the NKF-DOQI 
considerations (4). Others have chosen 650 or 750 mL/min (8,27). This may affect outcome. A 
recent meta-analysis by Paulson et al (36) concluded that a single Qa measurement did not appear 
to  have  enough  accuracy  to  be  a  clinically  useful  predictor  of  graft  thrombosis  or  failure. 
Furthermore,  it  has  been suggested  that  a  decrease  in Qa over  time of  >15% is  particularly 
predictive of impending graft failure (29). The present study was not specifically designed to 
study that issue. However, in the patients who were monitored by Qa measurements (Group A2 
and B2) none of the unpredicted thromboses were preceded by a decrease in Qa of more than 
15%. As a consequence, none of these thromboses would have been predicted by this criterion. 
Furthermore, in the patients who did not reach the threshold levels of the present study but did 
show a decrease in Qa of more than 15% (n = 11 (A2), n =  8 (B2); average decrease: 1090 
mL/min  to  740  mL/min)   none  experienced  thrombosis.  So,  our  data  do  not  support  the 
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hypothesis that a decrease in Qa of >15% as selection parameter would confer any benefit when 
added to either of the Qa protocols. Also, a recent study showed that a decrease in Qa over time 
had little predictive value (37).
In unmonitored PTFE grafts the total graft access event rate related to thrombosis or stenosis was 
1.51 per patient-year (7) of which 1.24 event per patient-year (82%) was caused by thrombosis. 
In the present studies the total graft  event rate  (related to thrombosis and stenosis)  was 1.88 
(range 1.69-2.27). On average, all thrombotic episodes accounted for 0.52 event per patient-year 
(28%) and the unpredicted thromboses accounted for 0.26 event per patient-year (14%). So, the 
introduction  of  a  well  structured  surveillance  program  resulted  in  a  substantial  decrease  in 
interventions for treatment of thrombosis at the expense of an increase of the number of elective 
interventions, mainly PTA. Our study was not designed as a cost effectiveness analysis. It seems 
likely, however, that this shift in type of interventions is associated with a decrease in access 
related morbidity and mortality.
What may be the implications of the present study for everyday clinical practice? We showed that 
using the surveillance protocol of this study outcome with respect to thrombosis rate is equal in 
Qa monitored grafts and in VP monitored grafts and that there is no rationale in combining the 
two methods.  It  is  important  to  note  that  our  population  contained  fewer  diabetics  than the 
average US dialysis  population.  It  is  possible that this affects outcome, since inflow stenosis 
(which will not be detected by VP measurements) may occur more frequently in diabetics. Each 
dialysis  center  should  decide  which  method  is  best  suitable  for  their  dialysis  practice.  VP 
measurements  are  easy  to  obtain  and  require  little  time  investment.  However,  they  need 
discipline.  Qa  measurements  are  more  time  consuming  and  a  special  device  is  needed.  We 
showed that by measuring Qa every 4 to 8 weeks identical results can be obtained as with weekly 
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VP assessments. The decision which method to use, will be primarily based on the preferences of 
those involved in the access care and on the possibilities to implement  a certain surveillance 
strategy. 
In conclusion, our studies show that standardized monitoring of VP or Qa or the combination of 
both  and subsequent  corrective  intervention  can  decrease  thrombosis  rates  to  below 0.5  per 
patient-year,  which  is  recommended  by  the  Vascular  Access  Task  Force  of  the  NKF-DOQI 
Committee as quality of care standard (4). When applying the present protocol, VP, Qa, or the 
combination as variables for selection of patients for corrective intervention are equally effective 
in reducing thrombosis rates in hemodialysis access grafts.
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Abstract
Background. Efficacy of percutaneous transluminal angioplasty (PTA) is usually expressed as the 
angiographic result. Access flow (Qa) offers a means to quantify the functional effect. This study 
was  performed to  evaluate  the  short-term functional  and angiographic  effect  of  PTA and to 
determine the longevity of the functional effect during follow-up.
Methods. Patients with an arteriovenous graft (AVG) or fistula (AVF) eligible for PTA (Qa<600 
mL/min) were included. Ultrasound-dilution derived Qa was measured shortly before PTA and 
periodically after PTA, starting 1 week after the procedure. The short-term effect was expressed 
as the increase in Qa and as the reduction of stenosis. The long-term effect was expressed as 
patency and as the decline in Qa after PTA.
Results. Ninety-eight  PTA procedures  in  60 patients  (65 AVG, 33 AVF) were analyzed.  Qa 
improved from 371±17 to 674±30 mL/min in AVG, and from 304±24 to 638±51 mL/min in AVF 
(both P<0.0001). In 66% (AVG) and 50% (AVF) flow increased to levels >600 mL/min. Degree 
of stenosis decreased from 65±3 % to 17±2 % in AVG and from 72±5 % to 23±7 % in AVF 
(both  P<0.005).  Reduction  of  stenosis  did  not  correlate  with  ∆Qa  (r2=0.066).  Six-month 
unassisted patency after PTA was 25% for AVG and 50% for AVF. Decline in Qa was 3.7±0.8 
ml/min/day in AVG and 1.8±0.9 ml/min/day in AVF. Qa before PTA and ∆Qa correlated with 
the subsequent decline in Qa (P<0.005).
Conclusions. Access flow increases after PTA, however in a substantial percentage not to a level 
>600  mL/min.  Qa  before  PTA  and  the  increase  in  Qa  correlated  with  long-term  outcome, 
whereas angiographic results did not. The present data combined with the literature suggest that 
there is an optimal timing for PTA.
98
Introduction
Vascular access complications account for considerable morbidity and mortality in hemodialysis 
patients. In the United States they are responsible for up to 25% of all hospitalizations in dialysis 
patients (1-3). The European Dialysis and Transplant Association does not collect data on this 
issue, but it is likely that data in Europe and elsewhere will be comparable. 
Thrombosis is the leading cause of vascular access complication. It is almost always associated 
with  the  presence  of  stenosis.  Percutaneous  transluminal  angioplasty  (PTA)  is  an  accepted 
treatment of stenotic lesions (3). Routine surveillance programs for the early detection of stenoses 
followed by angioplasty have been shown to substantially reduce the number of thromboses per 
patient  year  (4-7).  However,  repetitive  PTA  treatment  is  often  necessary,  since  re-stenosis 
frequently occurs. Although the short term success rates of PTA range from 85% to 98% (8), 
patency at 6 months follow-up varies from 38% to 63% (4,9-11). 
Several studies have shown that angiographic degree of the stenotic lesion before and after PTA 
is  poorly  related  with  its  subsequent  patency  (9,11-14).  Recently,  the  SCVIR  Technology 
Assessment  Committee  recommended  that  PTA  efficacy  should  be  expressed  by  both 
angiographic and functional parameters (15). In particular, access flow (Qa) measurements offer 
the opportunity to quantify and follow up the functional effect of PTA. 
The purpose of this study is to assess access function of patients undergoing PTA. We quantified 
the  short-term  functional  and  angiographic  effect  of  PTA.  Additionally,  we  determined  the 
longevity of the functional effect during follow-up. Finally, we addressed the question whether 
functional variables are predictive for long-term outcome. 
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Patients and methods
Patients
This prospective observational intervention study was done in 9 Dutch hemodialysis centers, in 
which a well-defined surveillance protocol was instituted as part of the routine patient care. All 
chronic hemodialysis patients with permanent arteriovenous grafts (AVG) and fistulae (AVF), 
who were referred for angiography because predetermined Qa threshold levels were reached, 
were eligible to enter the study. The surveillance protocol included periodic Qa measurements 
and angiography with PTA in thus selected patients.
Qa surveillance protocol
Qa was measured at least every 8 weeks using the ultrasound hemodilution technique (Transonic 
Systems Inc, Ithaca NY). The bench and clinical validations are presented elsewhere (16,17). 
The surveillance protocol has been discussed in detail previously (7). In brief, Qa determination 
consisted of the average of three single measurements within the first 30 minutes of the dialysis 
session at a fixed pump flow (> 200 mL/min). If Qa levels reached values between 600 and 800 
mL/min  the  measurement  was  repeated  at  least  every  4  weeks.  Patients  were  referred  for 
angiography whenever Qa was below 600 mL/min. Patients referred for angiography based on 
other criteria, for instance frequent miscanulation, swelling of the arm or high venous pressure, 
were  excluded.  Patients  with  a  history  of  allergy  to  iodinated  contrast  agents  were  also  not 
included into the study. 
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Angiography and percutaneous transluminal angioplasty (PTA)
Angiography and PTA procedures were done as soon as possible (usually < 7 days) after the low 
Qa level  (<  600 mL/min)  was  diagnosed.  Digital  subtraction  angiography was  performed to 
visualize the complete vascular access and to locate the stenosis. Any luminal reduction of 50% 
or more was treated by percutaneous transluminal angioplasty (PTA) during the same session. 
The same PTA technique was used for all patients. First, the stenotic lesion was crossed with a 
guide  wire  (Boston  Scientific  Corporation,  Watertown,  MA).  Then  a  sheath  was  introduced 
(Cordis Europe N.V., Roden, The Netherlands). The PTA balloon catheter was then passed over 
the  guide  wire  to  the  location  of  the  stenosis.  In  general,  the  high-pressure  balloons  had  a 
diameter of 6 mm although larger balloons (up to 10 mm) could be used for large proximal veins 
(Bülach, Switzerland). At the stenotic site the balloon was inflated to at least 10 atmospheres of 
pressure and held for approximately 2 minutes. In resistant cases pressures up to 20 atmospheres 
were used and held for 10 minutes.  No heparin,  vasodilators or local  anesthetics were given 
during the procedure. Immediately after PTA an angiogram was obtained to evaluate the result of 
the procedure. The interventional radiologist considered the PTA procedure successful when the 
residual diameter of the stenosis was less than 25%. After PTA, Qa measurements were done 
within one week and then at  least  at  4 weeks intervals.  In case Qa fell  below 600 mL/min, 
patients were referred for angiography and repeat PTA was performed if necessary. 
Outcome variables and statistical analysis
The short-term functional effect of PTA on Qa was evaluated by calculation of  ∆Qa, i.e. the 
difference between Qa before (Qapre) and just after PTA (Qapost). The long-term functional effect 
was assessed as the time to the next intervention, if applicable. When there were 3 or more Qa 
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measurements after the PTA, the decline in Qa was determined (in ml/min/day). Resistance was 
calculated as the ratio of mean arterial blood pressure (MAP) and Qa.
Angiographic data were analyzed by an independent radiologist. Only cases that had adequate 
biplanar angiograms available of the stenotic areas both before and after PTA were included. 
Stenosis degree was assessed before (baseline) and after PTA (post-PTA) as the ratio of maximal 
lumen reduction and an adjacent normal graft/vessel diameter (expressed in percentage: 0 % = no 
stenosis, 100 % = occlusion). Stenosis reduction due to PTA was calculated by the difference 
between baseline stenosis and post-PTA stenosis.
Data are presented as  mean ± SEM, unless indicated otherwise.  Differences of Qa and  ∆Qa 
values between different time points and subgroups of patients were calculated with two-tailed t-
tests.  Pearson analysis  was used for correlation purposes.  Post-PTA primary patency, i.e.  the 
period of  time  that  elapsed following intervention  until  access  thrombosis  or  re-intervention 
(surgical  and/or  radiological),  was  calculated  using life-table  analysis.  To compare post-PTA 
survival of AVF and AVG the (two-sided) log-rank test was performed.  P values of less than 
0.05 were considered significant.
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Results
Sixty  patients  referred  for  angiogram  were  included.  A  total  of  98  PTA  procedures  were 
performed. In 35 patients with an AVG, 65 PTA procedures were done. In the remaining 25 
patients with an AVF, 33 PTA procedures were performed. Patient and graft characteristics are 
shown in Table 1. 
Table 1. Patient and access characteristics
AVG AVF Total
Patients 35 25 60
Mean age in years (range) 62.7 (37.2 - 82.6) 66.8 (34.6 - 83.7) 64.4 (34.6 - 83.7)
Gender
     Male 6 16 22
     Female 29 9 38
Diabetes 9 (26%) 4 (16%) 13 (22%)
Coumarin therapy 19 (54%) 10 (40%) 29 (48%)
Mean age access in days (range) 629 (2 - 1893) 1088 (30 - 2926) 806 (2 - 2926)
Lower arm / upper arm 31 / 4 21 / 4 52 / 8
Functional results
Short-term. In all cases the first Qa measurement was done within 7 days after PTA, usually 
during the first dialysis session after PTA. 
In AVG, Qa improved from 371 ± 17 to 674 ± 30 mL/min (P < 0.0001). MAP remained stable 
after PTA (97 ± 2 vs 96 ± 2 mmHg), indicating that the increase in Qa represents a decrease in 
resistance. Qapost values greater than 600 mL/min were reached in 62% (40/65) (Figure 1A). A 
negative correlation was found between Qapre and the ∆Qa (P = 0.0019, r = -0.38). In diabetics 
Qapre did not differ from non-diabetics (340 ± 32 mL/min versus 386 ± 19,  P = 0.20). PTA in 
diabetics tended to be less effective than in non-diabetics (∆Qa, 228 ± 50 and 337 ± 41 mL/min 
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respectively, P = 0.06). The age of the AVG and of the patient did not correlate with ∆Qa. In 15 
patients multiple procedures were done (Table 2). In patients who were treated twice, ∆Qa was 
355 ± 68 ml/min and 424 ± 79 ml/min after the first and second PTA respectively (n = 15, P = 
ns). In patients who were treated 3 times,  ∆Qa was 315 ± 98, 484 ± 112 and 345 ± 51 ml/min 
after the first, second and third PTA respectively (n = 10, P = ns). In 15 patients, the PTA was the 
first intervention on the AVG. ∆Qa in those patients did not differ from those who had a second 
or later PTA (287 ± 61 vs. 313 ± 41 mL/min, P = 0.72). Unassisted patency did not differ either.
In AVF, Qa improved from 304 ± 24 to 638 ± 51 mL/min (P < 0.0001) (Figure 1B), 52% (17/33) 
of PTA procedures resulted in Qapost levels of more than 600 mL/min. The ∆Qa was not related to 
Qapre in AVF (r = -0.06). Diabetes or age of the AVF or patient did not significantly affect the 
results in AVF. Only four patients underwent 2 PTA procedures (Table 2) and showed a ∆Qa of 
541 ± 173 mL/min and 285 ± 144 mL/min after the first and second PTA respectively (P = 0.09).
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Table 2. Number of patients with single and multiple PTA procedures
AVG AVF Total
Single PTA 20 (20) 19 (19) 39 (39)
Multiple PTA 15 (45) 6 (14) 21 (59)
2 5 (10) 4 (8) 9 (18)
3 6 (18) 2 (6) 8 (24)
4 3 (12) - 3 (12)
5 1 (5) - 1 (5)
Total 35 (65) 25 (33) 60 (98)
Long-term. In 35% of all patients (21/60) multiple procedures were performed. In AVG, repeat 
PTA was more common than in AVF (43% (15/35) versus 24% (6/25) Table 2). In AVG, the 
mean time interval to re-PTA was shorter than in AVF (109 ± 12 and 169 ± 32 days, P = 0.04). In 
those with two PTA procedures, time interval between the first and second PTA was 113 ± 18 
days (n = 15). In those with three PTA procedures, time interval between the first and second and 
second and third PTA was 122 ± 26 and 101 ± 21 days respectively (n = 10, P = ns). 
Decline in Qa after PTA was 3.7 ± 0.8 ml/min/day in AVG (n = 38) and 1.8 ± 0.9 ml/min/day in 
AVF (n = 24) (P = 0.06). Coumarin use and diabetes did not affect the decline in Qa after PTA. 
However, there was a correlation between Qapre levels and the subsequent decline in Qa after 
PTA (r = -0.43, P < 0.005). Also, ∆Qa correlated with the decline in Qa after PTA  (r=-0.48, P = 
0.0009).
The median primary patency after PTA in AVG was 97 days. The post-PTA primary patency 
rates for AVG were at 1, 3 and 6 months 100%, 56% and 25% respectively. The median patency 
of AVF was 161 days. Post-PTA primary patency rates for AVF were at 1, 3 and 6 months 100%, 
92% and 50% respectively. 
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Log-rank comparison  analysis  of  intervention-free  survival  curves  demonstrated  a  significant 
difference in favor of the AVF (P = 0.031). 
During  the  available  follow-up  period  no  unpredicted  thrombotic  events  (i.e.  accesses 
thrombosed with a Qa >600 mL/min) occurred. In 6 AVG with a Qa that remained below 600 
mL/min after PTA, thrombosis occurred within weeks after PTA. These are considered predicted 
thromboses. Furthermore, some thromboses occurred in patients with low Qa while waiting for 
PTA.  These  accesses  were  not  included  in  this  analysis,  because  no  PTA  procedure  was 
performed.
Angiographic results 
In AVG, 48 (74 %) PTA procedures were performed on single lesions (38 (58 %) venous, 9 (14 
%) midgraft, and 1 (2 %) arterial stenosis). Seventeen (26 %) PTA procedures were done on two 
stenotic lesions (12 (18 %) showed a venous and midgraft stenosis, and 5 (8 %) had an arterial 
and venous stenosis). Log rank survival analysis showed no difference in patency between AVG 
with a single lesion versus those with multiple lesions (P = 0.74). Seven (21 %) PTA procedures 
in AVF were of true anastomotic lesions, twenty (61 %) were performed on venous lesions (in 
most  cases  located  within  the  first  few centimeters  from the  anastomosis)  and 6 (18 %) on 
combined  (venous  and  anastomotic)  lesions.  In  92%  of  all  PTA  procedures,  angiographic 
improvement  of  the  stenosis  was  achieved  using  a  6-mm  balloon.  Larger  balloons  were 
occasionally needed for proper dilatation of stenoses in proximal AVF veins. In all cases PTA 
was reported to be successful, i.e. residual luminal reduction of 25% or less.
In AVG, baseline stenosis was 65 ± 3 % and post-PTA stenosis 17 ± 2 % (n = 33, P < 0.0001). 
No correlation was found between baseline stenosis and post-PTA stenosis (r = -0.14, P = 0.47) 
or Qapost  (r = -0.05, P = 0.76). Baseline stenosis correlated with Qapre (r = -0.48, P = 0.008). No 
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correlation  was  found  between  angiographic  (=  stenosis  reduction)  and  functional  (∆Qa) 
improvement (r2 = 0.066) or between baseline stenosis and subsequent decline in Qa (r = -0.02, P 
= 0.93). Additionally, neither the stenosis reduction (P = 0.29) or the post-PTA stenosis (P  = 
0.07) correlated with the decline in Qa after PTA. Log rank survival analysis of the lower and 
upper 50th percentile baseline stenosis revealed no difference in survival (P = 0.90).
When the AVG group was divided in a group with Qapost <600 mL/min (n = 24) and a group with 
Qapost >600 mL/min (n = 41),  we found that  there was no difference in angiographic results 
between both groups. The group with Qapost <600 mL/min showed a stenosis of 66 ± 4 % before 
and 19 ± 4 % after PTA, while the group with Qapost  >600 mL/min had a stenosis of 63 ± 4 % 
before and 14 ± 3 % after PTA (P = NS). The group with Qapost <600 mL/min had a Qapre of 336 
± 24 mL/min and a Qapost of 441 ± 22 mL/min (∆Qa = 105 ± 24 mL/min). Those with Qapost >600 
mL/min had a Qapre of 392 ± 22 mL/min and a Qapost  of 811 ± 29 mL/min (∆Qa = 419 ± 40 
mL/min). Of the 24 patients with Qapost <600 mL/min, 6 thrombosed within 4 weeks after PTA, 8 
had a surgical correction without repeat angiogram, in 10 cases repeat angiograms showed 61% 
stenosis. Two of those patients were subsequently referred for surgical revision, and eight had 
another PTA. 
For the AVF, baseline stenosis was 72 ± 5 % and post-PTA stenosis was 23 ± 7 % (n = 8, P = 
0.0039). 
Discussion
To our  knowledge this  is  the  first  study in AVG and AVF reporting both  angiographic  and 
functional  results  of  PTA.  The  present  data  contain  novel  information.  We  show  that 
angiographic results do not correlate with functional results. Importantly, we demonstrate that 
functional variables are predictive for long-term outcome, whereas angiographic results are not. 
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The  study  confirms  recent  data  indicating  that  PTA  results  in  a  direct  increase  in  Qa  of 
approximately 250 mL/min (18). We also confirm that a substantial percentage of PTA is not 
successful. Finally, time to repeat PTA in the present study is substantially shorter than in other 
studies (9,18,19). This suggests a more rapid recurrence of stenosis in the present study. The 
combined data of these studies suggest that there is an optimal moment of PTA.
Based on the vast experience reported in the literature the NKF-K/DOQI taskforce has suggested 
PTA as one of the preferred treatments of vascular access stenosis (3). In most studies, the post-
PTA stenosis  is  used to express the efficiency of a  PTA procedure.  However,  the post-PTA 
stenosis  poorly  predicts  patency  after  PTA  (9,11-14).  Recently,  the  SCVIR  Technology 
Assessment  Committee  recommended  reporting  both  angiographic  and  functional  data  as 
efficacy variables of PTA (15). 
Our patients all had a Qa below 600 mL/min, which especially in grafts is a strong predictor for 
imminent thrombosis (3,20-23). They all had a baseline stenosis of 50% or more, which was 
treated by PTA. We confirm earlier data that on average Qa increases with approximately 250-
300 mL/min (18,24). In the patients with adequate angiograms, the post-PTA stenosis in AVG 
was in almost all cases 25% or less. This is considered to be an adequate angiographic result (3). 
However, the decrease in resistance did not correlate with the stenosis reduction, indicating that 
angiographic improvement does not necessarily represent functional improvement. Preliminary 
data in a small group of patients also indicated that the stenosis reduction did not correlate with 
the increase  in  Qa (14).  Results  in  diabetics  did not  differ  from those in  non-diabetics.  The 
percentage of PTA procedures resulting in a Qapost above the threshold value of 600 mL/min, was 
66% in AVG and 50% in AVF. Schwab et al. defined failure of PTA as an increase in Qa of less 
than 20%, which occurred in 21% of grafts (18). This lack of effect may be caused by rapid recoil 
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of  the  stenotic  lesion,  occurring  in  the  period  between  PTA  and  first  Qa  measurement. 
Intravascular ultrasound after PTA showed that immediate elastic recoil occurred in 50% of the 
stenotic lesions (25). The present findings may also indicate that other stenotic lesions, which 
importantly contribute to overall resistance, were not identified and not treated. Qa measurements 
during or immediately after PTA in the intervention room could be helpful to optimize procedure 
results (24). 
In patients who needed multiple procedures, similar increases in Qa were obtained in subsequent 
PTA procedures. This finding supports earlier data indicating that patency after repeat PTA does 
not decrease (9). Lumsden  et al.  randomized patients with greater than 50% stenosis to have 
either a PTA or no PTA and found that outcome did not differ (12). Later the same authors re-
analyzed  their  data  and  reported  that  patency  did  improve  but  only  in  grafts  without  prior 
angioplasty or thrombosis (13). In the present study only in a minority of AV grafts, the PTA 
included in this study was the first intervention. We were unable to confirm the earlier results, 
that outcome of a first intervention is better than that of a second or later intervention. 
Usually, long-term results of PTA are quantified as primary patency. In AVG, it varies from 38–
64% at 6 months and 10–40% at 12 months (8). We found an intervention-free primary patency 
at 6 months of 25% in AVG. The median time to next PTA was 97 days, as compared to 5.8 
months in the study by Schwab et al. (18). Their results seem substantially better than the present 
results, whereas the short-term functional effects in the two studies are comparable. Some of the 
differences between these studies may be important  in this respect.  In the present study,  AV 
grafts  were  almost  exclusively  localized  in  the  lower  arm,  whereas  Schwab’s  study  mainly 
included upper arm AVG. We selected patients when the threshold of 600 mL/min was reached, 
whereas in the other study most patients were referred when Qa showed a decrease of more than 
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20% or more. As a result, both Qa before and after PTA differed considerably, i.e. in the present 
study 371 ± 17 to 674 ± 30 mL/min  and in the  previous study approximately  750 and 950 
mL/min (18). The decline in Qa after PTA correlated with the Qapre level, suggesting that the 
severity of stenosis before PTA is predictive for the rate of stenosis recurrence. In patients with a 
Qapre level between 100 and 350 mL/min the decline in Qa was 4.1 ± 1.0 ml/min/day versus 2.7 ± 
1.2 ml/min/day for the patients with a Qapre level between 350 and 600 ml/min.  Further support 
for this notion comes from patients who underwent PTA because of high venous pressure and 
who were not included in this study. In these patients (n = 12) who had Qapre levels between 600 
and 800 ml/min, the decline in Qa was 1.6 ± 1.8 ml/min/day, which perfectly corresponds with 
the 5.8 months between consecutive interventions as reported by Schwab  et al. (18). Whereas 
baseline stenosis correlated with Qapre, post-PTA results (both post-PTA stenosis and stenosis 
reduction) did not correlate with the subsequent decline in Qa. These data suggest that Qa and 
therefore  resistance  is  more  predictive  for  longevity  of  effect  of  PTA than the  angiographic 
variables.  
Also, the correlation between the ∆Qa and the decline in Qa deserves comment. It is likely that a 
higher  ∆Qa is an indication of a greater dilation of the stenosis, probably corresponding with 
more  tissue  injury.  This  may  favor  more  rapid  stenosis  recurrence.  Indeed,  there  is  some 
indication that a less traumatic dilation, for instance by a cutting balloon, results in less activation 
of growth factors (reviewed in (23)).          
The combined results of the present study and the study by Schwab et al. (18) warrant the start of 
a new discussion on the optimal timing of PTA. It is tempting to hypothesize that post-PTA 
patency in AVG is related to Qapre and/or the functional result of the PTA. If this turns out to be 
the case, PTA should be done as soon as a decrease in Qa is found, as is advocated by some 
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(18,26), instead of when a low Qa level is reached as is proposed by others (7,27). In such cases a 
“mild” PTA may result  in  a better  long-term outcome than a more vigorous one.  Quality of 
patient  care  and  cost  effectiveness  of  PTA may  benefit  importantly  from properly  designed 
studies addressing this hypothesis.
Possibly the best way of quantifying the long-term effect of PTA is by calculating secondary 
patencies. However, the present study was not designed to address this question. Many patients 
were included in the surveillance and intervention program of the present study long after the day 
they had the access implanted. Some of them had undergone interventions before their inclusion 
in the study, making it impossible the express true secondary patency of AV grafts followed by 
the surveillance and intervention program as in the present study. However, survival estimation 
of our secondary patency rates for AVG revealed a 6-month patency of 85 %, a 1-year patency of 
79 %. In AVF, survival analysis showed a 6-month patency of 89 % and a 1-year patency of 82 
%. With the limitation outlined above in mind, we can conclude that our secondary patency is 
comparable to the data in the literature on secondary patency rates (3,8). 
The association between Qa and risk for thrombosis in AVF is less well documented than in 
AVG. AVF with Qa levels less than 300 to 500 mL/min can still remain patent (3). K/DOQI 
recommends  that  AVF  should  be  monitored  as  AVG.  The  efficacy  of  PTA  in  AVF  was 
comparable to that in AVG. The long-term effect in AVF seems substantially better than in AVG. 
Primary (post-PTA) patency in AVF ranges from 47-67% at  6 months and 16-62% after  12 
months (8). We found intervention-free primary patencies at  6 months of 50% and a median 
survival of 161 days for AVF. None of the investigated variables were predictive for the long-
term result in AVF. 
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In conclusion, access flow increases after PTA, however in a substantial percentage not to a level 
>  600 mL/min.  Qa  before  PTA and  the  increase  in  Qa  correlated  with  long-term outcome, 
whereas angiographic results did not. The present data combined with the literature suggest that 
there is an optimal timing for PTA.
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Introduction
An increased thrombotic tendency is an important cause of complications in patients on chronic 
hemodialysis  leading not only to possibly fatal complications like ischaemic heart disease, or 
stroke, but also to thrombosis of the vascular access (1). This latter complication remains the 
main  problem  in  vascular  access  for  haemodialysis,  particularly  in  polytetrafluoroethylene 
(PTFE) grafts. It accounts for considerable morbidity and mortality with an estimated annual cost 
of  close  to  $1  billion  in  the  United  States.  Moreover,  vascular  access  complications  mainly 
consisting of  thrombotic events  are  responsible  for  17-25% of  all  hospitalizations  in  dialysis 
patients (2-4).
In most cases thrombosis is associated with low access blood flow (5-7). The most important 
reason  for  a  decreasing  access  blood  flow  is  intimal  hyperplasia  formation  at  the  venous 
anastomosis or in the outflow tract of the graft (8-13). However, not all decreases in access blood 
flow are related to intimal hyperplasia or stenosis formation. Other causes for low access flow 
leading  to  access  thrombosis  have  been  proposed  (Table  1).  Hypotension,  hypovolaemia,  or 
external compression may be involved in these non-stenotic thrombotic events (14). Also, there 
has  been  a  growing  appreciation  of  the  role  of  increased  hypercoagulability  found  in  these 
patients. 
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Table 1. Possible causes of vascular access thrombosis
Low access blood flow
-intimal hyperplasia
-hypotension
-hypovolaemia
-external compression
Hypercoagulability
This  review  will  discuss  coagulability  abnormalities  in  relation  to  haemodialysis  access 
thrombosis.  First,  an  outline  will  be  given  regarding  normal  haemostatic  and  fibrinolytic 
responses. Subsequently, we will focus on coagulation abnormalities leading to the thrombotic 
tendency  in  chronic  haemodialysis  patients.  And  finally,  preventative  measures  for  these 
coagulation defects will be discussed.
Normal hemostasis and fibrinolysis
Normal  hemostatic  responses  are  initiated  by  damage  of  the  vessel  wall  with  exposure  of 
subendothelial  structures to flowing blood and results in the formation of a solid haemostatic 
plug. The first step of this hemostatic response involves platelet adherence to the subendothelium 
(15-17). The number of platelets available for this process is determined by platelet count. It is 
however,  even  more  dependent  on  red  blood  cell-mediated  transport  of  circulating  platelets 
towards the vessel wall (17-19). The adhesion of platelets to the site of injury is initially mediated 
by interactions between specific platelet receptors (e.g. glycoprotein Ib) and adhesive proteins in 
or deposited on the subendothelium (e.g. von Willebrand factor, vWF) (20-22). The quality of the 
platelet adhesion, however, depends strongly on subsequent platelet activation. Platelet activation 
is initiated by stimuli originating from the vessel wall but is sustained by products released from 
activated platelets themselves, for example thromboxane and adenosine diphosphate (ADP) (22). 
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Platelet  activation  leads  to  expression  of  additional  receptors  on  platelet  membranes  which 
support  platelet  interaction  with  subendothelium  (e.g.  glycoprotein  IIb/IIIa)  (22-25).  Most 
importantly, however, these receptors mediate platelet-platelet interactions resulting in aggregate 
formation.
Normal hemostasis also involves initiation of coagulation at sites of vessel wall injury that starts 
with activation of factor VII from flowing blood by tissue factor present in the vessel wall. The 
key products of the coagulation cascade are thrombin and fibrinogen. Thrombin proteolytically 
converts fibrinogen to insoluble fibrin, which in its turn activates factor XIII that causes cross-
linking of fibrin fibres (26). With collagen, thrombin is also a main stimulus of platelet activation 
and aggregation (22). Fibrin is able to stabilize platelet aggregates and other cellular elements in 
a  shear  stress  resistant  network.  Pathological  thrombin  formation  is  prevented  by  natural 
anticoagulant systems, of which antithrombin III and the vitamin K-dependent protein C systems 
are the most important ones. In addition to these anticoagulant systems the fibrinolytic system 
generates  plasmin  by  the  action  of  tissue  plasminogen  activator  on  plasminogen.  Plasmin 
dissolves the fibrin clot  and thereby prevents pathological  thrombus formation.  Thus,  normal 
hemostatic responses require both coagulation and platelet-dependent processes. 
In  hemodialysis  patients  complex  coagulation  abnormalities  occur  ranging  from bleeding  to 
thrombosis (1,27). On the one hand, the enhanced bleeding tendency in these patients is primarily 
based on functional platelet abnormalities and defective adhesion to the vessel wall (28,29). On 
the  other  hand,  a  variety  of  coagulation  abnormalities  contribute  to  an  increased  thrombotic 
tendency. 
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Factors in chronic hemodialysis patients contributing to thrombotic tendency 
Hypercoagulability in patients on chronic hemodialysis  can be caused by a variety of factors, 
mainly consisting of platelet abnormalities and plasma factor abnormalities (Table 2). 
Table 2. Factors contributing to an increased thrombotic tendency in patients on chronic 
haemodialysis
Platelet factors
-blood – artificial surface interaction
-treatment with recombinant human erythropoetin
-increased platelet count
-platelet activation due to high shear stress in the vascular access
Plasma factor abnormalities
-increased levels of vWF
-hyperfibrinogenaemia
-increased thrombin formation
-reduced levels of protein C anticoagulant activity
-high levels of factor VIII procoagulant
-decreased levels and reduced activity of antithrombin III
-impaired release of plasminogen activator
-increased levels of antiphospholipid antibodies 
-increased levels of homocysteine
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Platelet abnormalities
Platelet abnormalities are common in patients on hemodialysis. Paradoxically, most studies on 
platelet abnormalities in haemodialysis patients have focused on adhesion defects leading to an 
increased  bleeding  tendency.  So,  first  of  all,  do  these  platelets  actually  play  a  role  in  the 
thrombotic  tendency  seen  in  patients  on  hemodialysis?  In  other  words,  are  there  abnormal 
circumstances  leading  to  an  increase  of  thromboembolic  complications  in  a  setting  of 
dysfunctional platelets? Indeed, there are indications that this is the case. Although these platelet 
abnormalities exist which favour a bleeding tendency, other circumstances may actually lead to 
an increase in thrombotic complications. First of all, although some studies suggest a decreased 
membrane  expression  or  an  abnormal  activation  of  platelet  receptors  (glycoprotein  Ib  and 
IIb/IIIa)  (30,31),  an  increase  in  platelet  receptor  number  may  be  related  to  frequent  access 
obstruction  (32).  Also,  haemodialysis  is  thought  to  activate  platelets  by  adherence  to  the 
extracorporeal  circuit  (33,34).  In  addition  to  extracorporeal  activation,  high  shear  stress  and 
turbulence  in  the  vascular  access  may  be  responsible  for  further  platelet  activation  (35,36). 
Another condition favouring vascular access clotting is that the artificial surface of the PTFE 
graft,  and to a  lesser  extent  the native  arteriovenous (AV) fistula,  promotes  the  adhesion of 
fibrinogen (37,38). Serum fibrinogen, which is  increased in hemodialysis  patients,  adheres to 
glycoprotein IIb/IIIa on the surface of the platelet.  Once attached to the surface (solid phase 
fibrinogen) it can also bind to inactivated platelets, thereby activate them, and further enhance 
platelet deposition on the surface (37). Indeed, Windus et al.  (39) have shown that platelets are 
deposited along the vascular access surface. Another possible complementary explanation could 
be that clotting factor (contact factors like factor XII)  deposition may lead to local thrombin 
formation, platelet activation, and enhanced platelet deposition (40). 
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Adherent  platelets  may  release  factors  (platelet-derived  growth  factor  (PDGF),  for  example) 
which lead to or enhance intimal hyperplasia in the vascular access and thereby reduce blood 
flow through the access,  which allows other activated or non-activated platelets  to aggregate 
more easily. This creates, despite a bleeding tendency, a favourable situation for thrombosis. 
Plasma factor abnormalities
Uraemic subjects have higher levels of fibrinogen while at the same time thrombin formation is 
increased (41,42). Song et al. (43) showed that a high plasma fibrinogen level is an independent 
risk factor for vascular access failure in hemodialysis patients. In addition, levels of antithrombin 
III  may be  decreased and antithrombin  III  activity  may be  reduced  (44,45).  The subsequent 
increase of in vivo fibrinogen-fibrin transformation is reflected by increased fibrinopeptide A 
formation. 
Erdem  et al.  (46) also provided evidence for a substantial contribution of the vascular access 
itself to the modulation of the thrombotic tendency. By taking blood samples from the vascular 
access and from contralateral large veins in end-stage renal disease (ESRD) patients and from 
peripheral  veins  in  control  subjects,  they  showed  not  only  a  difference  in  parameters  of 
thrombotic tendency between peripheral vein samples in ESRD patients and controls, but more 
importantly,  also  between  vascular  access  samples  and  peripheral  vein  samples  in  the  same 
ESRD patient group. 
Others  have  shown  that  in  antiphospholipid  antibodies  are  predictive  of  vascular  access 
thrombosis  (45,47-49).  These  antibodies  include  lupus  anticoagulant  (LA),  anticardiolipin 
antibodies (ACA), and antiphosphatidyl serine antibodies. Higher titres of both ACA and LA 
antibodies  have  been  demonstrated  in  patients  with  ESRD  than  in  the  general  population 
(48,50,51).   Elevated LA antibody titres are present in up to one-third of hemodialysis patients 
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(48). Elevated ACA antibody titres have been found in 0-29% of them (48,52,53), with a greater 
prevalence in patients with AV grafts (22%) than with native AV fistulae (6%) (47).  However, 
the association between elevated ACA antibody titre and increased access thrombosis is not fully 
established  yet.  While  several  studies  found  no  association  (48,52,54),  Prakash  et  al.  (47) 
demonstrated  in  a  retrospective  study  a  3.7  times  increased  risk  of  recurrent  thrombosis  in 
patients with PTFE grafts having elevated ACA antibody titres. The latter finding was recently 
confirmed in a prospective study: the survival time of PTFE grafts in patients with elevated titres 
was significantly shorter than in patients with normal titres. Interestingly, this difference was not 
found in patients with native AV fistula (53). 
Hyperhomocysteinaemia  is  an  independent  risk  factor  for  recurrent  and  early-onset  venous 
thrombosis in patients with normal renal function (55-57). Fasting homocysteine levels have been 
shown to be elevated in patients  with ESRD (58) and may contribute  to  atherosclerosis  and 
subsequent cardiovascular events in haemodialysis patients (59,60). The underlying mechanism 
by which hyperhomocysteinaemia provokes thrombosis is uncertain. It may involve a change in 
factor V and protein C complex activity as well as effects on platelet function (56,61,62).
Studies on the association of homocysteine and access thrombosis are limited and the results are 
controversial. In a retrospective study by Manns et al. (52) no association between homocysteine 
level  and  access  thrombosis  was  found.  Two  recent  prospective  studies  showed  conflicting 
results. Shemin et al. (63) demonstrated a 4% increase in the risk of access thrombosis with each 
1µmol/l  increase  of  plasma  homocysteine  concentration  for  both  AV  fistulae  and  grafts. 
Similarly, Ducloux et al. (64) suggested that hyperhomocysteinaemia is a risk factor for vascular 
access thrombosis. However, such an association could not be demonstrated in a population of 96 
patients with only native AV fistulae. The patients with the lowest levels even appeared to have 
an increased mortality risk (65). These conflicting differences in outcome may be related to the 
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type  of  fistula,  to  the  length  of  follow-up,  and  to  other  variables.  Obviously,  long-term 
prospective studies with serial, instead of occasional, determinations of plasma homocysteine are 
needed to solve this issue. 
Therapeutic considerations
Anti-platelet therapy
The usefulness of antiplatelet therapy for the maintenance of internal hemodialysis access devices 
was reviewed by the Antiplatelet Trialists’ Collaboration Group (66). Outcomes of nine placebo-
controlled randomized trials showed an occlusion rate of 17% in the antiplatelet groups vs 39% in 
the  control  groups.  Antiplatelet  regimens  consisted  of  ticlopidine  (five  studies),  aspirin  (two 
studies), and sulphinpyrazone (two studies). Unfortunately, most of the evaluated studies were 
conducted  in  the  late  1970s  and  the  beginning  of  the  1980s.  At  that  time  some  of  the 
achievements in modern dialysis were not yet available, and dialysis populations differed from 
those of today. Moreover, these studies had only a short follow-up (mean 2 months). Finally, the 
analysis report was difficult to interpret in terms of excess bleeding due to antiplatelet therapy.
Only one randomized, placebo-controlled clinical trial comparing access thrombosis frequency in 
patients treated with antiplatelet therapy (dipyridamole 75 mg orally 3 times a day, or aspirin 325 
mg orally daily) was conducted in the last decade. Surprisingly, dipyridamole alone, which is 
considered a relatively weak platelet inhibitor, had the best outcome, while patients on aspirin 
had the highest frequency of thrombosis, even higher than with placebo or the combination of 
dipyridamole and aspirin (67). The results of this study became more understandable after the 
authors conducted a series of in vitro experiments using vascular smooth muscle cells (68,69). 
They  could  show  that  aspirin  potentiated  PDGF-induced  vascular  smooth-muscle  cell 
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proliferation by shunting arachidonic acid from cyclo-oxygenase into lipoxygenase pathways. On 
the other hand, dipyridamole profoundly inhibited PDGF- and bFGF-induced vascular smooth-
muscle cell proliferation. This suggests that the observed direct effect of aspirin and dipyridamole 
on  vascular  smooth-muscle  cell  proliferation  (rather  than  the  antiplatelet  effect)  is  a  better 
explanation  for  the  reported  clinical  efficiency  of  dipyridamole.  Gastrointestinal  bleeding 
occurred in 16% of the treated patients vs 8% in the placebo group. Unfortunately, no anatomical 
data or functional data (e.g. vascular access flow) was collected in the randomized trial (67). This 
could have provided further in vivo evidence for the experimental in vitro data.
Finally, Windus et al.  (70) showed that aspirin and ticlopidine both reduced dialysis-associated 
platelet deposition in PTFE grafts, although they did not completely prevent it. 
Oral anticoagulation
Current  opinions  on the  use  of  systemic  anticoagulant  therapy to  improve access  patency is 
primarily based on personal belief rather than on evidence. Not surprisingly, the reason is that 
systematic  data  on  this  subject  are  very limited.  Interestingly,  despite  the  lack  of  consensus 
nephrologists  do  not  refrain  from  prescribing  anticoagulants.  As  a  consequence  numerous 
different  anticoagulant  strategies  exist  from  centre  to  centre  as  to  patient  selection,  dosing 
scheme, and treatment duration. 
In 1967, the effect of coumadin in reducing the clotting frequency of AV Scribner shunts was 
first reported in three dialysis patients (71). A few years later coumadin was shown to prolong 
cannula  shunt  life  in  non-uraemic  sheep  (72).  However,  in  several  recent  studies  aimed  at 
evaluating risk factors for vascular access dysfunction, anticoagulants were either not used in the 
study population or their use was not mentioned. Nevertheless, the use of anticoagulants was 
advocated based on the hypercoagulable state often found in the dialysis  patients under study 
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(48,73).  In  a  recent  Japanese  study  in  83  dialysis  patients  with  AV fistula  dysfunction,  no 
association  was  found  with  prior  anticoagulant  use  or  prothrombin  time  (74).  However,  the 
criteria mentioned for fistula dysfunction were vague and the distribution of various access types 
(AV fistula or PTFE) in this population was not mentioned. Dialysis patients with a history of 
early vascular access graft loss or frequent thrombosis showed a twofold prolongation of access 
survival  time and less  frequent  clotting  after  initiation  of  coumadin  (53,75).  However,  these 
results  were  based  on  small  numbers  and  obtained  with  patients  being  their  own  controls. 
Bleeding  complications  seen  in  these  studies  occurred  in  patients  with  high  international 
normalized ratio (INR) levels. Also, LeSar et al. (45) showed in a subgroup of dialysis patients 
with  frequent  PTFE  graft  thrombosis  and  a  hypercoagulable  state  (i.e.  prevalence  of 
antiphospholipid  antibodies,  anti-thrombin  III  and  protein  C system abnormalities),  that  oral 
anticoagulant therapy effectively decreased thrombosis frequency, particularly with INR values 
maintained at 2.7-3.0. However, the incidence of significant bleeding complications in this subset 
of  patients  was  10% per  year.  By administering  coumadin,  Valeri  et  al.  (53) increased  the 
survival of access grafts in 16 patients with elevated ACA antibody titres and frequent access 
thrombosis.  However,  the  absolute  duration  of  graft  survival  in  the  treated  group  was  not 
impressive (48 ± 12 days in the untreated group vs 103 ± 26 days in the patients on coumadin 
with target INR values of 2.0-3.0). Two patients suffered major bleeding complications, although 
both had an overshoot of target INR (> 8). 
Conclusion
Despite the bleeding tendency of chronic hemodialysis patients, vascular access thrombosis is a 
frequent complication. Hypercoagulability is one of the causes contributing to the high frequency 
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of access thrombosis. The hypercoagulable state can be explained by platelet and coagulation 
factor  abnormalities.  Unfortunately,  few randomized placebo-controlled trials  were conducted 
using antiplatelet or oral anticoagulation therapy. Therefore, no evidence-based consensus has 
been established regarding pharmacological prevention of access thrombosis. It still needs to be 
determined whether the potential benefits of anticoagulation and antiplatelet therapy outweigh the 
risk of adverse events. In the meantime it seems reasonable to give some form of anticoagulant 
therapy  based  on  pathophysiological  considerations  and  the  high  incidence  of  thrombotic 
complications. Our group recently demonstrated that graft flow measurements could effectively 
predict thrombotic vascular access events (76). Risk tables that take into account such parameters 
as well as plasma markers of hypercoagulability may help to develop rationally designed trials 
and guidelines.
127
 References
1. Lindner A, Charra B, Sherrard DJ, Scribner BH Accelerated atherosclerosis in prolonged 
maintenance hemodialysis.  N Engl J Med 1974; 290:697-701
2. Feldman HI, Kobrin S, Wasserstein A: Hemodialysis vascular access morbidity.  J Am 
Soc Nephrol 1996; 7:523-35
3. USRDS:  The  economic  cost  of  ESRD,  vascular  access  procedures,  and  Medicare 
spending for alternative modalities of treatment. United States Renal Data System.  Am J 
Kidney Dis 1997; 30 (Suppl 1):S160-S77
4. Feldman HI, Held PJ, Hutchinson JT, Stoiber E, Hartigan MF, Berlin JA: Hemodialysis 
vascular access morbidity in the United States.  Kidney Int 1993; 43:1091-6
5. Bosman PJ, Boereboom FTJ, Eikelboom BC, Koomans HA, Blankestijn PJ: Graft flow as 
a predictor of thrombosis in hemodialysis grafts.  Kidney Int 1998; 54:1726-30
6. Smits JHM, Blankestijn PJ:  Haemodialysis access: the case for prospective monitoring. 
Curr Opin Nephrol Hypertens 1999; 8:685-90
7. Diskin CJ, Stokes TJJ, Pennell AT: Pharmacologic intervention to prevent hemodialysis 
vascular access thrombosis.  Nephron 1993; 64:1-26
8. Bassiouny HS, White S, Glagov S, Choi E, Giddens DP, Zarins CK: Anastomotic intimal 
hyperplasia: mechanical injury or flow induced.  J Vasc Surg 1992; 15:708-16
128
9. Kanterman RY,  Vesely  TM,  Pilgram TK,  Guy BW,  Windus  DW,  Picus  D:  Dialysis 
access grafts: anatomic location of venous stenosis and results of angioplasty.  Radiology 
1995; 195:135-9
10.Roberts  AB,  Kahn MB,  Bradford  S, Lee  J,  Ahmed Z,  Fitzsimmons  J,  Ball  D:  Graft 
surveillance  and  angioplasty  prolongs  dialysis  graft  patency.   J  Am Coll  Surg 1996; 
183:486-92
11.Safa AA, Valji K, Roberts AC, Ziegler TW, Hye RJ, Oglevie SB: Detection and treatment 
of dysfunctional  hemodialysis  access  grafts:  effect  of  a  surveillance  program on graft 
patency and the incidence of thrombosis.  Radiology 1996; 199:653-7
12.Smits  HF,  Van  Rijk  PP,  Van  Isselt  JW,  Mali  WP,  Koomans  HA,  Blankestijn  PJ: 
Pulmonary embolism after thrombolysis of hemodialysis grafts.  J Am Soc Nephrol 1997; 
8:1458-61
13.Smits JHM, Blankestijn  PJ:  Thrombosis-free hemodialysis  grafts:  a possibility for the 
next century?  Semin Dial 1999; 12:44-9
14.Windus DW: Permanent vascular access: a nephrologist's view.  Am J Kidney Dis 1993; 
21:457-71
15.Sakariassen KS, Bolhuis PA, Sixma JJ: Platelet adherence to subendothelium of human 
arteries in pulsatile and steady flow.  Thromb Res 1980; 19:547-59
16.Baumgartner  HR:  The  role  of  blood flow in  platelet  adhesion,  fibrin  deposition,  and 
formation of mural thrombi.  Microvasc Res 1973; 5:167-79
129
17.Turitto  VT,  Weiss  HJ,  Baumgartner  HR:  Rheological  factors  influencing  platelet 
interaction with vessel wall surfaces.  J Rheol 1979; 23:735-49
18.Aarts PA, Bolhuis PA, Sakariassen KS, Heethaar RM, Sixma JJ: Red blood cell size is 
important for adherence of blood platelets to artery subendothelium.  Blood 1983; 62:214-
7
19.Aarts  PA, Heethaar  RM, Sixma JJ:  Red blood cell  deformability  influences  platelets-
vessel wall interaction in flowing blood.  Blood 1984; 64:1228-33
20.Stel HV, Sakariassen KS, de Groot PG, van Mourik JA, Sixma JJ: Von Willebrand factor 
in the vessel wall mediates platelet adherence.  Blood 1985; 65:85-90
21.Coller BS, Peerschke EI, Scudder LE, Sullivan CA: Studies with a murine monoclonal 
antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: 
additional evidence in support of GPIb as a platelet receptor for von Willebrand factor. 
Blood 1983; 61:99-110
22.Sixma JJ, Wester J: The hemostatic plug.   Semin Hematol 1977; 14:265-99
23.Niiya  K,  Hodson  E,  Bader  R,  Byers-Ward  V,  Koziol  JA,  Plow  EF,  Ruggeri  ZM: 
Increased surface expression of the membrane glycoprotein IIb/IIIa complex induced by 
platelet  activation.  Relationship  to  the  binding  of  fibrinogen and platelet  aggregation. 
Blood 1987; 70:475-83
24.Ruggeri ZM, De Marco L, Gatti L, Bader R, Montgomery RR. Platelets have more than 
one binding site for von Willebrand factor.  J Clin Invest 1983; 72:1-12
130
25.Solum NO: Procoagulant expression in platelets and defects leading to clinical disorders. 
Arterioscler Thromb Vasc Biol 1999; 19:2841-6
26.Furie B, Furie BC: Molecular and cellular biology of blood coagulation.  N Engl J Med 
1992; 326:800-6
27.Eberst  ME,  Berkowitz  LR:  Hemostasis  in  renal  disease:  pathophysiology  and 
management.  Am J Med 1994; 96:168-79
28.Castillo  R,  Lozano  T,  Escolar  G,  Revert  L,  Lopez  J,  Ordinas  A:  Defective  platelet 
adhesion on vessel subendothelium in uremic patients.  Blood 1986; 68:337-42
29.Escolar G, Cases A, Bastida E Garrido M, Jopez J,  Revert L, Castillo R, Ordinas A: 
Uremic  platelets  have  a  functional  defect  affecting  the  interaction  of  von Willebrand 
factor with glycoprotein IIb-IIIa.  Blood 1990; 76:1336-40
30.Sloand JA, Sloand EM: Studies on platelet membrane glycoproteins and platelet function 
during hemodialysis.  J Am Soc Nephrol 1997; 8:799-803
31.Benigni A, Boccardo P, Galbusera M Monteagudo J, De Marco L, Remuzzi G, Ruggeri 
ZM: Reversible activation defect of the platelet glycoprotein IIb-IIIa complex in patients 
with uremia.  Am J Kidney Dis 1993; 22:668-76
32.Liani  M,  Salvati  F,  Tresca  E Di  Paolo  G,  Vitacollona  L,  Golado  M,  Velussi  C: 
Arteriovenous fistula obstruction and expression of platelet receptors for von Willebrand 
factor and for fibrinogen (glycoproteins GPIb and GPIIb/IIIa) in hemodialysis patients. 
Int J Artif Organs 1996; 19:451-4
131
33.Hakim  RM,  Schafer  AI:  Hemodialysis-associated  platelet  activation  and 
thrombocytopenia.  Am J Med 1985; 78:575-80
34.Cases A, Reverter JC, Escolar G Sanz C, Lopez-Pedret J, Revert L, Ordinas A: Platelet 
activation on hemodialysis: influence of dialysis membranes.  Kidney Int 1993; 43 (Suppl 
41): S217-S20
35.Turitto VT, Hall CL: Mechanical factors affecting hemostasis and thrombosis.  Thromb 
Res 1998; 92:S25-S31
36.Viener A, Aviram M, Better OS, Brook JG: Enhanced in vitro platelet  aggregation in 
hemodialysis patients.  Nephron 1986; 43:139-43
37.Savage  B,  Ruggeri  ZM:  Selective  recognition  of  adhesive  sites  in  surface-bound 
fibrinogen  by  glycoprotein  IIb-IIIa  on  nonactivated  platelets.   J  Biol  Chem 1991; 
266:11227-33
38.Salzman EW, Lindon J,  McManama G, Ware JA: Role of fibrinogen in activation of 
platelets by artificial surfaces.  Ann N Y Acad Sci 1987; 516:184-95
39.Windus DW, Santoro S, Royal HD: The effects of hemodialysis on platelet deposition in 
prosthetic graft fistulas.  Am J Kidney Dis 1995; 26:614-21
40.Colman  RW,  Scott  CF,  Schmaier  AH,  Wachtfogel  YT,  Pixley  RA,  Edmunds  LHJ: 
Initiation of blood coagulation at artificial surfaces.  Ann N Y Acad Sc. 1987; 516:253-67
41.Sagripanti  A,  Cupisti  A,  Baicchi  U,  Ferdeghini  M,  Morelli  E,  Barsotti  G:  Plasma 
parameters of the prothrombotic state in chronic uremia.  Nephron 1993; 63:273-8
132
42.Tomura S,  Nakamura  Y, Deguchi  F,  Ando R, Chida Y,  Marumo F:  Coagulation and 
fibrinolysis  in  patients  with  chronic  renal  failure  undergoing  conservative  treatment. 
Thromb Res 1991; 64:81-90
43.Song  IS,  Yang  WS,  Kim  SB,  Lee  JH,  Kwon  TW,  Park  JS:  Association  of  plasma 
fibrinogen concentration with vascular access failure in hemodialysis patients.  Nephrol  
Dial Transplant 1999; 14:137-41
44.Lai KN, Yin JA, Yuen PM, Li PK: Effect of hemodialysis on protein C, protein S, and 
antithrombin III levels.  Am J Kidney Dis 1991; 17:38-42
45.LeSar  CJ,  Merrick  HW,  Smith  MR:  Thrombotic  complications  resulting  from 
hypercoagulable states in chronic hemodialysis vascular access.  J Am Coll Surg 1999; 
189:73-9
46.Erdem  Y,  Haznedaroglu  IC,  Celik  I,  Yalcin  AU,  Yasavul  U,  Turgan  C,  Caglar  S: 
Coagulation,  fibrinolysis  and  fibrinolysis  inhibitors  in  haemodialysis  patients: 
contribution of arteriovenous fistula.  Nephrol Dial Transplant 1996; 11:1299-1305
47.Prakash R, Miller CC, Suki WN: Anticardiolipin antibody in patients  on maintenance 
hemodialysis  and its  association with recurrent  arteriovenous graft  thrombosis.   Am J 
Kidney Dis 1995; 26:347-52
48.Brunet P, Aillaud MF, San Marco M, Philip-Joet C, Dussol B, Bernard D, Juhan-Vague I, 
Berland  Y: Antiphospholipids  in  hemodialysis  patients:  relationship  between  lupus 
anticoagulant and thrombosis.  Kidney Int 1995; 48:794-800
133
49.Prieto  LN,  Suki  WN:  Frequent  hemodialysis  graft  thrombosis:  association  with 
antiphospholipid antibodies.  Am J Kidney Dis 1994; 23:587-90
50.Garcia-Martin F, De Arriba G, Carrascosa T, Moldenhauer F, Martin-Escobar E, Val J, 
Saiz  F: Anticardiolipin  antibodies  and lupus  anticoagulant  in  end-stage  renal  disease. 
Nephrol Dial Transplant 1991; 6:543-7
51.Sitter  T,  Schiffl  H:  Anticardiolipin  antibodies  in  patients  on regular  hemodialysis:  an 
epiphenomenon?  Nephron 1993; 64:655-6
52.Manns BJ, Burgess ED, Parsons HG, Schaefer JP, Hyndman ME, Scott-Douglas NW: 
Hyperhomocysteinemia,  anticardiolipin  antibody  status,  and  risk  for  vascular  access 
thrombosis in hemodialysis patients.  Kidney Int 1999; 55:315-20
53.Valeri  A,  Joseph  R,  Radhakrishnan  J:  A  large  prospective  survey  of  anti-cardiolipin 
antibodies in chronic hemodialysis patients.  Clin Nephrol 1999; 51:116-21
54.George J, Aron A, Levy Y, Gilburd B, Ben-David A, Renaudineau Y, Zonana-Nachach 
A, Youinou P,  Harats  D, Shoenfeld Y: Anti-cardiolipin,  anti-endothelial-cell  and anti-
malondialdehyde-LDL  antibodies  in  uremic  patients  undergoing  hemodialysis: 
relationship  with  vascular  access  thrombosis  and  thromboembolic  events.  Hum 
Antibodies 1999; 9:125-31
55.Boushey CJ,  Beresford  SA,  Omenn GS,  Motulsky  AG:  A quantitative  assessment  of 
plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing 
folic acid intakes.  JAMA 1995; 274:1049-57
134
56.Den Heijer M, Blom HJ, Gerrits WB, Rosendaal FR, Haak HL, WijermansPW, Bos GM: 
Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis?  Lancet 1995; 
345:882-5
57.Selhub J, D'Angelo A: Relationship between homocysteine and thrombotic disease.  Am J 
Med Sci 1998; 316:129-41
58.Bostom AG, Lathrop L: Hyperhomocysteinemia in end-stage renal disease: prevalence, 
etiology, and potential relationship to arteriosclerotic outcomes.  Kidney Int 1997; 52:10-
20
59.Bostom AG,  Shemin  D,  Verhoef  P,  Nadeau MR,  Jacques  PF,  Selhub  J,  Dworkin  L, 
Rosenberg  IH: Elevated  fasting  total  plasma  homocysteine  levels  and  cardiovascular 
disease  outcomes  in  maintenance  dialysis  patients.  A  prospective  study.  Arterioscler  
Thromb Vasc Biol 1997; 17:2554-8
60.Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW, Robinson K, 
Dennis VW: Prospective study of hyperhomocysteinemia as an adverse cardiovascular 
risk factor in end-stage renal disease. Circulation 1998; 97: 138-41
61.McCully  KS,  Carvalho  AC:  Homocysteine  thiolactone,  N-homocysteine  thiolactonyl 
retinamide,  and  platelet  aggregation.   Res  Commun  Chem  Pathol  Pharmacol 1987; 
56:349-60
62.Graeber JE, Slott JH, Ulane RE, Schulman JD, Stuart MJ: Effect of homocysteine and 
homocystine on platelet and vascular arachidonic acid metabolism.  Pediatr Res 1982; 
16:490-3
135
63.Shemin D,  Lapane KL,  Bausserman L, Kanaan E,  Kahn S,  Dworkin  L,  Bostom AG: 
Plasma total homocysteine and hemodialysis access thrombosis: a prospective study.  J 
Am Soc Nephrol 1999; 10:1095-9
64.Ducloux D, Pascal B, Jamali M, Gibey R, Chalopin JM: Is hyperhomocysteinaemia a risk 
factor for recurrent vascular access thrombosis in haemodialysis patients?  Nephrol Dial  
Transplant 1997; 12:2037-8
65.Sirrs  S,  Duncan  L,  Djurdjev  O,  Nussbaumer  G,  Ganz  G,  Frohlich  J,  Levin  A: 
Homocyst(e)ine and vascular access complications in haemodialysis patients: insights into 
a complex metabolic relationship.  Nephrol Dial Transplant 1999; 14:738-43
66.Collaborative overview of randomised trials of antiplatelet therapy- II: Maintenance of 
vascular  graft  or  arterial  patency  by  antiplatelet  therapy.  Antiplatelet  Trialists' 
Collaboration.  BMJ 1994; 308:159-68
67.Sreedhara  R,  Himmelfarb  J,  Lazarus  JM,  Hakim  RM:  Anti-platelet  therapy  in  graft 
thrombosis: results of a prospective, randomized, double-blind study.  Kidney Int 1994; 
45:1477-83
68.Harvey R, Bredenberg CE, Couper L, Himmelfarb J: Aspirin enhances platelet-derived 
growth  factor-induced  vascular  smooth  muscle  cell  proliferation.   J  Vasc  Surg 1997; 
25:689-95
69.Himmelfarb  J,  Couper  L:  Dipyridamole  inhibits  PDGF-  and  bFGF-induced  vascular 
smooth muscle cell proliferation.  Kidney Int 1997; 52:1671-7
136
70.Windus  DW,  Santoro  SA,  Atkinson  R,  Royal  HD:  Effects  of  antiplatelet  drugs  on 
dialysis-associated platelet deposition in polytetrafluoroethylene grafts. Am J Kidney Dis 
1997; 29:560-4
71.Wing AJ, Curtis JR, De Wardener HE: Reduction of clotting in Scribner shunts by long-
term anticoagulation.  Br Med J 1967; 3:143-5
72.Boyd SJJ, Dennis MB, Nogami RT, Cole JJ, Scribner BH: Prophylactic coumadin and A-
V cannula function.  J Appl Physiol 1974; 37:6-7
73.Ambühl PM, Wüthrich RP, Korte W, Schmid L, Krapf R:. Plasma hypercoagulability in 
haemodialysis patients: impact of dialysis and anticoagulation.  Nephrol Dial Transplant 
1997; 12:2355-64
74.Masaki T, Yorioka N, Kyuden Y, Yamashita K, Taniguchi Y, Yamakido M, Tanaka J, 
Harada S: Factors influencing arteriovenous fistula dysfunction in Japanese patients on 
chronic hemodialysis.  Int J Artif Organs 1999; 22:14-7
75.Tevlin MT, Portner ME, Kraus MG, Dulaney JT:  Clotting frequency of hemodialysis 
accesses before and after systemic anticoagulation with coumadin.  J Am Soc Nephrol 
1996; 7:1421 (Abstract)
76.Blankestijn PJ, Smits JH: How to identify the haemodialysis access at risk of thrombosis? 
Are flow measurements the answer?  Nephrol Dial Transplant 1999; 14:1068-71
137
Chapter 8
SUMMARY AND GENERAL DISCUSSION
138
Summary and general discussion
Since the introduction of the AV fistula and the use of interposition graft little improvement has 
been made in the vascular access field. Still, vascular access related complications, are one of the 
most  important  reasons  for  patient  hospitalization,  morbidity  and  even  mortality  (1,2). 
Interestingly, the costs of vascular access related care was found to be more than fivefold higher 
for patients with AVG compared with patients with a functioning AVF (3). In an attempt to 
improve  overall  patency  rates  and  reduce  access  related  costs,  the  NFK-DOQI  committee 
currently recommends that in any dialysis  center the majority of new dialysis  patients should 
have a primary AVF constructed (4,5). Unfortunately, creation of an AVF  is not always possible 
as  a  consequence of  prior  vascular  access  surgery,  insufficient  caliber  of  forearm vessels  or 
sclerosis caused by prior venipunctures. Although less thrombotic and infectious complications 
occur in AVF, the AVF is not ideal,  i.e. 100% successful.  Adequate maturation of AVF, i.e. 
sufficient dilatation and arterialization, fails in up to 30% of all newly created fistulae, resulting 
in  delayed  initiation  of  dialysis  treatment  or  placement  of  temporary  central  venous dialysis 
catheters, and related morbidity (6-10). Optimalization of patient selection could improve AVF 
patency  rates  and  access  related  morbidity.  Considering  the  increasing  age  of  hemodialysis 
patients,  prolongation  of  the  dialysis  therapy,  and  the  worldwide  increase  of  the  number  of 
patients  requiring  hemodialysis,  the  number  of  AV grafts  will  probably  increase  rather  than 
decrease. As a consequence, vascular access complications, particularly thrombosis, will continue 
to challenge vascular access care in the future.
In chapter 3 we examined the importance of pre-operative forearm venous distensibility with 
respect to AVF maturation. With the recognition of the superiority of the AVF and the increasing 
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comorbidity of the hemodialysis population, efforts are made to evaluate the vasculature of the 
arm of  the  patient  prior  to  access  surgery.  This  prospective  study evaluates  forearm venous 
function rather than anatomy prior to AVF creation for the first time. The results of this study 
confirm our hypothesis that apart from structural changes, the functional properties of forearm 
veins  are  important  in  the  adaptive  response  to  increased  blood  flow  after  AVF  creation. 
Furthermore,  functional  data  of  forearm vasculature  do not  correspond with anatomical  data. 
Importantly, we demonstrate that venous distensibility is predictive of the potential success of 
AVF  construction  and  adequate  maturation,  whereas  venous  and  arterial  diameters  are  not. 
Finally, our study confirms recent data indicating that AVF flow measured one day after surgery 
is  higher  in  AVF  with  successful  maturation  in  compare  to  AVF  that  fail  to  mature  (11). 
Considering our data support the hypothesis that functional vessel  wall characteristics predict 
fistula maturation, the preoperative evaluation of the forearm vasculature should not only focus 
on resting static diameters. In view of the large potential benefits of optimization of the matching 
of patients and access type, further and larger studies of novel techniques are urgently needed. 
In  chapter 4, we determined whether  forearm blood flow capacity in patients with end-stage 
renal  failure  awaiting  vascular  access  surgery,  is  predictive  of  early  failure  of  AVF.  We 
hypothesized that forearm blood flow capacity, i.e. the increase of forearm blood flow as a result 
of vasodilatation, is an important determinant of failure of newly created AVF in hemodialysis 
patients. To discriminate the influence of the endothelium in early fistula failure, we measured 
both  endothelium  dependent  (i.e.  metacholine-induced)  and  endothelium  independent  (i.e. 
sodium  nitroprusside-induced)  forearm  vasodilatation,  using  forearm  venous  occlusion 
plethysmography.  To our knowledge, this is the first time invasively measured forearm blood 
flow capacity is related to outcome of AVF. This study shows that pre-operative forearm blood 
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flow capacity is predictive of early AVF failure. Especially, the AUC of dose response curves 
seems predictive of AVF outcome.  An AUC of 100 in MCh and 200 in NP seems a prerequisite 
of short term success of the AVF. Furthermore, our data indicate that AVF failure is not the result 
of pure endothelial dysfunction, because endothelial-independent forearm blood flow capacity is 
also diminished in patients with AVF failure. Structural arterial wall changes can be responsible 
for this finding (12). Finally, we showed that arterial diameter is not predictive of early AVF 
failure.  Venous occlusion plethysmography has the advantage of measurement of  total forearm 
blood flow.  However,  clinical  implementation  of  venous occlusion plethysmography prior  to 
access surgery is not simple. First, this technique is very time-consuming and expensive devices 
are needed. Second, and even more important, it is an invasive measurement. Future research 
should focus on easier and non-invasive methods to measure pre-operative arterial flow reserve.
Chapter 5 explored the effect of monitoring and selection for corrective interventions based on 
VP and/or Qa, on thrombosis rates of AVG. This study confirms the usefulness of VP and Qa 
measurements  as  access  surveillance variables:  thrombosis  rates  in  our  patients  can  be 
maintained below the quality of care standards formulated by the NKF-DOQI committee (13). 
Based on the hypothesis that stenoses located in the flow tract upstream the venous needle would 
not  by  picked  up  by  VP  measurements,  we  expected  Qa  measurements,  or  combined 
measurement of Qa and VP, to be superior as a monitoring tool, in compare to VP measurements 
alone (14). This hypothesis is not confirmed in our study: thrombosis rates in groups monitored 
by VP or Qa alone or by the combination of tests do not differ. We found a strong predominance 
of venous lesions in the patients referred for angiography or thrombectomy. In less than 5% of 
patients referred for angioplasty arterial lesions were found. It is possible that in patients who 
develop more arterial lesions, surveillance using Qa would result in lower thrombosis rates than 
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using  VP  measurements.  Our  study  confirms  previous  evidence  that  dynamic  VP  does  not 
accurately reflect resistance caused by stenosis formation, since most referrals for intervention in 
patients  monitored  by VP measurements  alone  were based  on  static  VP measurements  (15). 
Dynamic VP is highly biased by pump flow, blood tubing, needle size, and blood pressure (16). 
Static  VP  measurements,  on  the  other  hand,  particularly  when  corrected  for  mean  arterial 
pressure, avoid these potential confounders.        
Our study results indicate that the decision which method to use, (static) VP or Qa, can in fact be 
based on the preferences of those involved in the access care. There is no rationale in combining 
VP and Qa monitoring. It is important to bear in mind that a monitoring strategy can only be 
successful when abnormal tests are followed by diagnostic and interventional procedures on short 
notice. This is illustrated by the fact that almost one third of all thrombotic events in this study 
occurred in patients awaiting angiography.
In  chapter 6 we assessed hemodialysis  access  function in patients  undergoing PTA. To our 
knowledge this is the first study in AVG and AVF reporting both angiographic and functional 
results of PTA. This study confirms earlier data that PTA results in an immediate access flow 
increase of about 250 mL/min (17). Although post-PTA stenosis poorly predicts patency after 
PTA, the post-PTA stenosis is frequently used to express the efficiency of the procedure (18). We 
demonstrated that adequate angiographic improvement, i.e. 25% or less post-PTA stenosis, does 
not necessarily correspond with adequate functional improvement,  i.e. access flow above 600 
mL/min. More important, we found functional parameters are predictive for long-term outcome, 
whereas angiographic results are not. Whereas almost all PTA procedures were angiographically 
successful,  only 66% of AVG and 50% of AVF obtained adequate access flow. This may be 
caused by rapid elastic recoil of the stenotic lesion or may reflect other unidentified and thus 
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untreated stenoses.  Access flow measurements  during,  or  just  after  the intervention  could be 
helpful to overcome this problem and optimize PTA results (22-24). Finally, time to repeat PTA 
in our study is substantially shorter than in other studies (19-21,25). This suggests a more rapid 
recurrence of stenosis in the present study. This difference may reflect differences in stenosis 
severity prior to PTA, as a result of more strict selection criteria for referral for angiography. The 
combined data of these studies suggest there is an optimal moment of PTA.
Chapter 7 reviews  coagulability abnormalities in relation to hemodialysis  access thrombosis. 
An increased thrombotic tendency is an important cause of ischaemic heart disease, stroke, and 
vascular access thrombosis in chronic hemodialysis patients (26). Although most cases of access 
thrombosis  are  associated  with  low access  blood  flow,  caused by intimal  hyperplasia  in  the 
venous outflow tract,  in  a  number  of  cases,  thrombosis  is  not  preceded  by low access  flow 
measured during hemodialysis. Hypotension, hypovolemia and external compression during the 
interdialytic  period  are  proposed  mechanisms  of  these  non-stenotic  thrombotic  events  (27). 
However,  several  coagulability  abnormalities  may  attribute  to  access  thrombosis.  Platelet 
abnormalities are common in patients on hemodialysis. Obviously, dysfunctional platelets favor a 
bleeding tendency. However, other circumstances may create a favorable situation for thrombotic 
complications.  Adherence  of  platelets  to  the  extracorporal  circuit,  high  shear  stress  and 
turbulence in the vascular access may be responsible for exaggerated platelet activation (28-31). 
The  artificial  surface  of  the  polytetrafluoroethylene  material  of  AVG  promotes  adhesion  of 
fibrinogen on platelet receptors, thereby activating them, and adhancing platelet deposition on the 
surface  (32).  High  plasma fibrinogen  and  elevated  titers  of  antiphospholipide  antibodies  are 
shown  to  increase  the  risk  of  access  failure  (33-38).  Hyperhomocysteinemia  has  also  been 
proposed as potential risk factor of access thrombosis (39,40). However, studies on this subject 
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are limited and the results are controversial. Obviously, long-term prospective studies with serial, 
instead of occasional determinations of plasma homocysteine are needed to address this problem. 
What are the clinical  implications of these findings? Unfortunately, few randomized placebo-
controlled trials were conducted using antiplatelet or oral anticoagulation therapy. Therefore, no 
evidence-based consensus has been established regarding pharmacological prevention of access 
thrombosis. Furthermore, it remains questionable whether the benefits of antithrombotic therapy 
outweigh the risk of bleeding complications. In the meantime it seems reasonable to give some 
form of anticoagulant therapy based on pathophysiological considerations and the high risk of 
thrombotic  complications.  Future  research  on  hemodynamic  factors  affecting  the  lifespan  of 
vascular accesses should also take into account plasma markers of hypercoagulability. Because 
personal belief is an important factor in prescribing anticoagulant therapy, it seems unlikely that 
long-term placebo-controlled trials will be started in the near future.
Future perspectives
The nephrologist is primarily responsible for the management of patients with renal failure, both 
before and after initiation of dialysis treatment. Together with the patient he makes the decision 
as to when hemodialysis should begin. According to the National Kidney Foundation’s recent 
Clinical  Practice  Guidelines,  patients  with ESRD should be prepared for  dialysis  when their 
glomerular filtration rate is less than 25 mL/min. This provides sufficient time for maturation and 
incorporation of the access. More accurate coordination between the placement of a fistula or 
graft and the initiation of dialysis may avoid the need of central venous catheters. Furthermore, 
timely  referral  to  a  nephrologist  is  associated  with  a  higher  proportion  of  patients  starting 
hemodialysis on a functioning AVF and a lower overall mortality. Planning a vascular access 
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strategy for the individual patient well in advance of dialysis however, is best accomplished in a 
multidisciplinary setting, in which all efforts are made to create native AVF if possible.  
Doppler ultrasound has been the most extensively studied and widely used test to guide access 
creation. However, we have demonstrated that seemingly adequate vessel diameter alone does 
not guarantee successful outcome of AVF. The influence of functional variables like forearm 
blood flow reserve and venous distensibility on the outcome of AVF has never been studied 
before and should be addressed extensively in future studies. Pre-existing endothelial dysfunction 
and structural wall changes are proposed mechanisms of forearm vessel dysfunction in patients 
with ESRD. Once the role of endothelial dysfunction on outcome of AVF is clarified, it would be 
very interesting to explore the effects of medications that could prevent endothelial cell injury 
prior  to  access  surgery,  like  statins  or  angiotensin  converting  enzyme  inhibitors.  Intimal 
hyperplasia is a well-known cause of access thrombosis. However, it has become clear that these 
intimal changes can be demonstrated in most of the apparently normal cephalic veins in ESRD 
patients at  the time of AVF construction (41). Although several efforts are made to decrease 
intimal  hyperplasia  after  access  creation,  it  would  be  of  interest  to  study  the  effect  of 
pharmacological inhibition of intimal hyperplasia in advance of access creation.
Patients aged 65 or more undergoing dialysis, have a life-expectancy of approximately 3 years, 
and life-expectancy in the oldest age groups is very limited. Therefore, dialysis in the elderly 
remains  a  challenge  and  raises  the  question  whether  it  is  proper  to  offer  expensive  and 
complicated treatment to a growing worldwide population of older patients with renal failure. 
Although DOQI Vascular  Access Guidelines strongly recommand the contruction of AVF in 
elderly,  it  seems  reasonable  to  consider  other  options  in  elderly  patients  with  short  life 
expectancy from other comorbidities or chronic hypotension. Recently,  the Dialock system, a 
device  totally  implanted  under  the  pectoral  skin  and  inserted  in  the  subclavian  vein,  was 
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demonstrated  to  be  safe  and  effective  in  “complex”  hemodialysis  patients.  Infection  and 
complication  rates  of  this  device  were  even  lower  in  compare  to  permanent  central  venous 
catheters  and AVG (42,43).  It  remains  to  be  elucidated  whether  this  device  is  useful  in  the 
elderly. Also, the cost-effectiveness of this approach needs to be addressed. 
Over the past years the effectiveness of access surveillance has been demonstrated. Prospective 
surveillance  of  vascular  accesses  for  hemodynamically  significant  stenoses,  and  subsequent 
referring for percutaneous transluminal angioplasty or surgical revision, improves patency rates 
and decreases the incidence of thrombosis. At present, access flow (Qa) and venous pressure 
measurements are preferred techniques that can be used in surveillance of both AVG and AVF. 
However, structural access surveillance still needs to be introduced in many dialysis centers. An 
adequate  surveillance  strategy can only succeed in an enthusiastic  team with affinity  for the 
vascular access, consisting of a nephrologist, vascular surgeon, radiologist and nursing staff.
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Dankwoord
Zoals  waarschijnlijk  voor  elke  promovendus  geldt,  was  ook  dit  proefschrift  een  enorme 
bevalling.  Sterker  nog,  een  bevalling  is  minder  erg!  Gedurende  geruime  tijd  en  met  ruime 
tussenpozen, ben ik bezig geweest met het onderzoek wat heeft geleid tot het schrijven van dit 
proefschrift. Ik heb hierbij gaandeweg heel veel mensen leren kennen, die stuk voor stuk hebben 
bijgedragen  aan  mijn  motivatie  het  onderzoek  ook  waardig  af  te  sluiten  met  een  promotie! 
Klinisch onderzoek staat  of  valt  bij  de bereidwilligheid  van patiënten.  Een ereplaats  in  deze 
opsomming  is  dan  ook  wel  verdiend.  Allereerst  wil  ik  dan  ook  alle  dialyse  en  pre-dialyse 
patiënten bedanken voor hun medewerking aan de onderzoeken. Hun continue doorzettingskracht 
en getoonde interesse in mijn vorderingen hebben mij erg geïnspireerd. Daarnaast heeft het ook 
veel gezellige momenten opgeleverd, met name tijdens de flowmetingen op de dialyseafdeling. 
Voor het schrijven van dit proefschrift is de wetenschappelijke en/of sociale bijdrage van vele 
anderen onmisbaar, daarom wil ik graag de volgende personen bedanken.
Uit angst conventioneel te zijn heb ik me mogen scharen tussen maar liefst twee co-promotoren. 
Dr. M.A. van den Dorpel, beste René, ik ben ervan overtuigd dat ik het niet had gered zonder 
jouw  geduld  en  doorzettingsvermogen.  Jij  hebt  de  gave  alles  vanuit  een  positieve  kant  te 
benaderen.   Daarnaast  heeft  onze  langdurige  samenwerking  ook  hele  gezellige  en  grappige 
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momenten opgeleverd. Het heeft wat koude grond psychologie van jouw zijde gevergd, maar het 
resultaat is er! Wat zul je blij zijn dat het af is (in meerder opzichten). Je relativerende oordeel 
over patiëntenzorg blijkt in de praktijk trouwens volledig te kloppen!
Dr. P.J. Blankestijn, beste Peter, ik bewaar goede herinneringen aan onze telefonische meetings, 
waarin  in  korte  tijd  spijkers  met  koppen  geslagen  konden  worden.  Dr.  J.H.M.  Smits,  beste 
Sander, jij hebt het er al even (!) opzitten. Het voelt echter nog steeds alsof ik onze eer moet 
verdedigen! Ik hoop dat jij wel bij mijn verdediging aanwezig kunt zijn! Zonder jullie inbreng 
van Utrechtse zijde, had mijn proefschrift nooit tot stand kunnen komen.
Prof. Dr. W. Weimar, beste Willem, hartelijk bedankt dat je mijn promotor hebt willen zijn. De 
leden van de beoordelingscommissie,  Prof.dr. P.M.T. Pattynama, Prof.dr. H. van Urk en Prof.dr. 
H.A.P. Pols, wil ik bedanken voor hun deelname in de promotiecommissie en het kritisch lezen 
van mijn proefschrift.
Het is een onmogelijke taak alle medewerkers van de dialyse-afdeling van het Clara Ziekenhuis, 
persoonlijk te bedanken. Desalniettemin zijn jullie stuk voor stuk onmisbaar geweest voor het 
verzamelen van mijn data, het motiveren van patiënten om mee te werken aan mijn onderzoek en 
niet te vergeten het motiveren van deze dokter! Gezellig waren ook de droppings, waarbij ik eens 
bijna mijn rug brak in een greppel, doordat een zekere broeder het nodig vond om op mijn rug te 
springen.  Hanneke Pernot,  als  onze  eerste  echte  onderzoeksnurse  heb je  mijn  werk een stuk 
gemakkelijker gemaakt, zeker toen ik weer in de kliniek zat. Jouw doortastendheid en zeker ook 
brutaliteit hebben geleid tot heel wat data. Wat hebben we veel geouwehoerd, gemopperd, maar 
ook gelachen! Hiervoor mijn eeuwige dank!
Voor mijn onderzoek was de samenwerking met de vaatchirurgen, Dr. Yo en André de Smet, 
maar ook de afdeling Radiologie, zowel radiologen als laboranten., van meet af aan een must. Via 
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deze weg wil ik hen dan ook bedanken voor het laagdrempelige overleg en hun bereidwilligheid. 
Op deze plaats verdient ook Drs Burgmans speciale aandacht. Lieve Ine, het was zeker geen 
makkelijke tijd, maar gezellig was het altijd wel. Met name aan San Antonio (ik heb nog leuke 
but-foto’s) en Tours bewaar ik hele goede herinneringen!
Na alle flow- en drukmetingen, brak het plethysmografie-tijdperk aan. Dr. Van den Meirakker, 
beste Ton, ik wil je bedanken voor de mogelijkheden die ik, als niet EMC-er kreeg, gebruik te 
maken van ‘jouw’afdeling en je wetenschappelijke input bij het opstellen van de protocollen, en 
het  schrijven  van  mijn  artikelen.  Dr.  Lameris,  lieve  Thomas,  aan  jou  ben  ik  veel  dank 
verschuldigd. Of het nou ging om een postertje, de plethysmograaf, een abstract, een artikel of 
een persoonlijk advies,  je was er altijd! Vergeleken bij  jou voelde ik me altijd een complete 
wetenschappelijke  analfabeet.  Als  ik  iets  sneller  was  geweest,  had  het  anders  gelopen. 
Desalniettemin, alle lof en mijn eeuwige dank! Als ik aan plethysmografie denk, denk ik direct 
aan de meiden van het Inwendige I lab. Bianca, Marjolein en Evelien, het waren tropenjaren! 
Werkelijk alles wat mis kon gaan ging mis, maar met z’n allen wisten we het probleem toch altijd 
weer op te lossen. Jullie geduld, vindingrijkheid maar vooral ook gezelligheid, is onvergetelijk!
Lieve Jacqueline, Jack voor intimi,  hoe kan ik jou beter bedanken, dan vragen –alsnog- mijn 
getuige te zijn bij deze ‘bruiloft in mijn ééntje’. In die lange tijd dat ik je nu ken ben je er altijd 
voor me geweest en heb je me ook altijd gesteund, no matter what! Met jou kan ik keihard lachen 
én janken, liefst allemaal op één avond. Ik ben er erg trots op dat je mijn vriendin bent en dat jij 
als paranymf aan mijn zijde zal staan op deze belangrijke dag in mijn leven. 
Dr. Wittich, lieve Philip, in ruil voor al je gezelligheid en ontspannende momenten, vergeef ik je 
dat ik niks aan je heb als paranymf (eigen woorden!). Het levert hoe dan ook een mooi plaatje op, 
en een hoop stof tot discussie. Ik ben blij dat je erbij bent!
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Lieve ouders, jullie wil ik bedanken voor al jullie steun de afgelopen jaren. Zowel in praktische 
(de zorg voor mij en Boris), als in mentale zin (jullie hebben me altijd vrijgelaten om die dingen 
te doen die ik graag wilde doen), zijn jullie onmisbaar geweest voor mijn carrière en niet op de 
laatste  plaats  de  afronding  van  dit  proefschrift.  Ma,  dit  is  nou  een  moment  om  eens  niet 
bescheiden te zijn: je bent fantastisch in alles wat je doet!
Lieve Rob, ik heb het je niet gemakkelijk gemaakt de afgelopen jaren. Ik ben jou oneindig veel 
dank verschuldigd voor je eeuwige geloof in mij. Mede daardoor kwam het boekje af. Je hebt me 
enorm veel gegeven, waarbij Boris bovenaan staat en ons altijd zal blijven verbinden!
Tenslotte wil ik alle familie en vrienden bedanken voor de zo broodnodige ontspanning in tijden 
van stress.  Ik ben zeker niet de meest attente maar  wel de meest chaotische zus en vriendin 
denkbaar, maar nu deze last van mijn schouders is gevallen, durf ik jullie beterschap te beloven! 
Lieve X.,  zonder sentimenteel te worden, hoop ik met heel mijn hart,  dat everlasting eeuwig 
duurt!
Allerliefste Boris, mijn o zo grote maar nog kleine man, mama is er klaar mee! Het wordt weer 
eens tijd voor een vliegreisje dacht ik zo...
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